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Abstract 
 
Among the public health relevant disorders, Type 1 Diabetes (T1D) is a degenerative 
disease affecting almost 2 million Americans. It is characterized by the loss of insulin-producing 
β-cells due to a T cell-mediated autoimmune response. The risk to develop T1D is HLA 
associated. HLA-DQ8-DR4 has been identified as the most prevalent HLA haplotype in the 
Caucasian T1D population. Although DQ8 has been demonstrated to be the primary genetic 
determinant of disease susceptibility, its predisposing effect is likely modulated by the 
expression of closely linked DR4 alleles. As one of hypotheses to explain the role of DR4 
molecules in T1D etiology, the peptide competition model holds that DR4 competes to bind 
diabetogenic peptides with DQ8 and thus affects DQ8-restricted autoreactive CD4 T cell 
responses. However, the evidence of the competition is insufficient due to the lack of detection 
reagents and the difficulty of segregating the expression of DR4 from DQ8. In this study, we 
investigated the competition of peptides derived from Glutamic Acid Decarboxylase 65 
(GAD65) – a putative β-cell autoantigen. A panel of DQ8-restricted T cell lines was generated to 
serve as detection reagents to evaluate the peptide occupancy of DQ8. After demonstrating that a 
single peptide derived from GAD65 could bind both HLA-DQ8 and HLA-DR4, we compared 
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CD4 T cell responses elicited by antigen presenting cells expressing DQ8 alone with those 
expressing DQ8 and DR4 simultaneously. Results indicated that the co-expression of HLA-DR4 
diminished DQ8-restricted T cell responses. In addition, distinct DR4 subtypes were 
demonstrated to affect DQ8-restricted T cell responses differently, suggesting the variable 
degrees of peptide competition potentials. Taken together, this study provides the evidence that 
DR4 is able to compete for peptides with DQ8. The outcome of this competition decreases DQ8-
restricted CD4 T cell responses, which may hence contribute to a peripheral tolerance 
mechanism and explain the modulating role of DR4 to the DQ8-conferred T1D susceptibility.  
 
 
Massimo Trucco, MD 
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1.0  INTRODUCTION 
HLA-DQ and HLA-DR are MHC class II molecules constitutively expressed on the surface of 
human antigen presenting cells (APCs) such as B cells, macrophages, and dendritic cells. The 
function of HLA-DQ and DR is to present antigenic peptides and initiates CD4 T cell responses 
(1). Both DQ and DR molecules are composed of an α-chain and a β-chain. Genes encoding DQ 
and DR subunits are located at the short arm of chromosome 6. DR α-chain gene is non-
polymorphic, whereas DR β-chain and DQ α-/β- chain genes are highly polymorphic. 
 
Specific HLA-DQ-DR haplotypes are associated with various autoimmune diseases such 
as human Type 1 Diabetes (T1D), which is characterized as the cell-mediated destruction of 
insulin-producing pancreatic β-cells (2, 3). It has been demonstrated that a single amino acid 
polymorphism at the position 57 of DQ β-chain (Asp57β vs. non-Asp57β) is associated with 
increased risk to develop T1D (4, 5). Asp57β alleles such as DQB1*0602 and DQB1*0301 
confer dominant disease resistance, whereas non-Asp57β alleles such as DQB1*0302 and 
DQB1*0201 render disease susceptibility. 
 
Among the Caucasian T1D population, HLA-DQ8 (DQA1*0301/DQB1*0302)-DR4 
(DRB1*0401) is the most prevalent haplotype (6). Current understanding of this haplotype in the 
progression of the disease is that the non-Asp57β DQ8 molecule is defective in directing 
efficient negative selection of autoreactive CD4 T cells during the T cell development in the 
thymus (7). Some of these CD4 T cells are potentially reactive against β-cell autoantigens such 
as insulin and glutamic acid decarboxylase 65 (GAD65). In a concert with certain types of viral 
infection or other poorly identified environmental factors, these autoreactive CD4 T cells are 
activated in the periphery and initiate β-cell specific autoimmune responses, which cause 
insulitis and β-cell death. When majority of β-cell mass is lost, diabetes occurs.   
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The role of DR molecules in the disease progression, however, is defined quite 
differently. Although the frequency of DRB1*0401 is high in diabetic patients, it is mainly due 
to its strong linkage disequilibrium with highly susceptible DQ8 alleles (6). Results from DQ8-
matched case-control studies have indicated that different DQ8-DRB1*04 haplotypes are 
associated with variable risks in a hierarchical rank of DQ8-DRB1*0405 > DQ8-DRB1*0402 > 
DQ8-DRB1*0401 > DQ8-DRB1*0404 (RR=1)> DQ8-DRB1*0403 or 0406 (8, 9). DQ8-
DRB1*0405/0402/0401 are susceptible, DQ8-DRB1*0404 is neutral and DQ8-
DRB1*0403/0406 are strongly resistant. This rank suggests that DR4 subtypes composed of 
different DRB1*04 alleles provide variable degrees of protection to T1D in the order of 0405 < 
0402 < 0401 < 0404 < 0403 or 0406. In addition, by using HLA transgenic mice that also 
transgenically express the co-stimulatory molecule CD80 in β-cells, it has been demonstrated 
that the co-expression of DR4 (DRB1*0401) with DQ8 diminishes the incidence of spontaneous 
diabetes (10). Taken together, these studies suggest that DR4 molecules modulate the T1D 
susceptibility conferred by DQ8. However, the mechanisms by which those DR4 manifest the 
effect are still under investigation.  
 
A peptide competition model has been proposed to address the combined effect of DQ8 
and DR4 to the risk of T1D (11). It hypothesizes that DR4 competes with DQ8 for β-cell-derived 
peptides responsible for the activities of autoreactive CD4 T cells, which escape from negative 
selection due to the defect of DQ8. The outcome of DR4-DQ8 competition results in reduced 
peptide occupancy of DQ8 on the surface of APCs and diminishes peptide-driven autoreactive 
CD4 T cell responses. Hence, it provides a straightforward explanation to the hierarchical 
association between T1D and those DQ8-DRB1*04 haplotypes. It is noteworthy that 
polymorphic residues among this panel of DRB1*04 alleles are mostly located in the peptide 
binding site and directly involved in peptide presentation. Thus, these polymorphisms might 
render distinct DR4 subtypes variable peptide competition potentials that differently affect DQ8-
restricted autoreactive CD4 T cell activities. A strong DR competitor is associated with 
decreased T cell activities, whereas a weak DR competitor is associated with increased T cell 
activities. 
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This study aimed to develop an in vitro experimental system and provide the evidence to 
define the role of DR4 molecules regarding their peptide competition capabilities. We started 
from preparing reagents that were required to evaluate the peptide occupancy of DQ8 molecules. 
It was accomplished by generating a panel of T cell lines and hybridomas from HLA-DQ8 
transgenic mice that were immunized by candidate peptides. These T cell reagents were also 
characterized regarding their specificities and purities to ensure that the quality satisfied the 
requirement of peptide presentation evaluation. Four steps were then applied to test the 
hypothesis of DR4-DQ8 competition. In the first step, a candidate peptide – hGAD65206-220 was 
demonstrated to be capable of binding to both DQ8 and DR4. The second step was to examine 
whether the presence of DR4 (0401) would diminish DQ8-restricted T cell responses. This was 
achieved by comparing T cell responses elicited by DQ8+DR4- to DQ8+DR4+ APCs, which were 
obtained from different HLA transgenic mice since they were the most available sources of 
APCs segregating DQ8 from DR4 expression. To further confirm the role of DR4 competition, 
another T cell assay was applied in the presence of a peptide blockade that occupied DR4 peptide 
binding sites to neutralize DR4 peptide binding activity. We observed that T cell responses were 
partially recovered. The third step was to evaluate effects of different DRB1*04 alleles. With the 
comparison of T cell responses induced by a panel of human B cell lines that expressed distinct 
DQ8-DRB1*04 haplotypes, we demonstrated that B cells bearing T1D resistant DQ8-
DRB1*0403/0406 haplotype and neutral DQ8-DRB1*0404 were less capable of triggering T cell 
responses than those expressing susceptible DQ8-DRB1*0402 and DQ8-DRB1*0401 
haplotypes. In the end, we attempted to deliver a candidate peptide hGAD65539-547 into 
intracellular compartments where HLA-DQ8 and DR4 were synthesized. It was accomplished by 
forcing an artificial APC – COS7 cell line to synthesize the candidate peptide endogenously from 
the transfected recombinant invariant chain cDNA that carried the peptide coding sequence. This 
endogenously synthesized peptide was presented by DQ8 onto the surface and caused the T cell 
response. However, in the presence of DR4, the T cell response was reduced. 
 
In summary, we not only provided the evidence to demonstrate that DR4 was able to 
compete for peptides with DQ8, but also showed that the potential of competition was associated 
with polymorphisms (within the peptide binding site) that distinguished high risk DQ8-
DRB1*04 haplotypes from low risk ones. With this improved understanding to the role of DR4 
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in affecting DQ8 peptide presentation in this in vitro system, it is tantalizing to use the HLA 
transgenic mouse model to further pursue the outcome of DR4-DQ8 peptide competition under 
the in vivo system regarding the generation, activation and regulation of DQ8-restricted 
autoreactive T cells. These events all depend on the amount of peptide:DQ8 complexes. Given 
the DQ8-DR4 is the most common haplotype in the Caucasian population, the knowledge toward 
the overall effect of this haplotype should always be considered in the attempt to develop 
immunotherapeutic strategies to interfere in the progression of autoimmune diabetes. 
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2.0  REVIEW OF RELEVANT LITERATURE 
2.1 Etiology of T1D 
2.1.1 Clinical manifestation 
Type 1 Diabetes (T1D) or insulin-dependent diabetes mellitus (IDDM) is by far the most 
common serious metabolic disorder in children (12). It is characterized as the hyperglycemia and 
absolute lack of insulin production due to the loss of pancreatic β-cells. Although exogenous 
insulin administration prevents death caused by insulin-deficiency, it is not able to cure the 
disease and leads to a variety of life-span complications such as T1D-related eye disease, kidney 
dysfunction, cardiovascular disease and neuropathy syndromes. As a consequence of 
microvascular pathology in the retina and renal tissues, T1D is now the leading cause of new 
cases of blindness in people aged 20-74. T1D patients are the fastest growing group of recipients 
for renal dialysis and kidney transplantation. Over 60% of these patients are affected by 
neuropathy. In conjunction with lower extremity arterial disease, T1D accounts for 50% of all 
non-traumatic amputations in the United States. Furthermore, the risk for developing 
cardiovascular complications is increased 2-fold to 6-fold in subjects with T1D (13). Their life 
expectancy is about 7-10 years shorter than normal healthy subjects (14).  
2.1.2 T1D is an autoimmune disease 
Distinguished from Type 2 Diabetes (or non-insulin-dependent diabetes mellitus, NIDDM) that 
is defined as either insufficient insulin-secretion by pancreatic β-cells or improper taking up of 
insulin by peripheral tissues, T1D is characterized as the selective autoimmune destruction of 
insulin-producing β-cells. By the onset of T1D, the β-cell mass is mostly destroyed and the C-
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peptide (a post-translation side-product of proinsulin) level in the blood is below detection, 
indicating that no insulin is produced. 
 
T1D shares several common features (2) with other autoimmune diseases. First, the 
disease state can be transferred to a healthy subject by the patients’ antibodies or T cells. It was 
supported by a report of an accidental transmission of the disease to a 29-year-old aplastic 
anemia-affected woman who developed T1D 4 years after receiving bone marrow transplantation 
from her HLA-identical diabetic brother (15, 16). The circulating leukocytes (B lymphocytes and 
T lymphocytes) were confirmed to be male-donor type by chromosomal analysis. It indicated 
that the disease was not spontaneous but was caused by the lymphocytes from the donor’s bone 
marrow.  
 
More details about the role of lymphocyte subsets have been further elucidated by studies 
using animal models of T1D such as the non-obese diabetic mouse (NOD). NOD is one of the 
most intensively investigated animal models of T1D (17). This strain was originally established 
in Japan by inbreeding of Jcl:ICR progenitors in 1980 (18). Many sub-strains are now available, 
though they differ from each other with certain variation of spontaneous diabetes incidence. In 
high-incidence colonies, 80-90% of female NOD mice are diabetic by 24 weeks of age, whereas 
incidence of male NOD mice is lower and more fluctuating, typically >40 % by the age of 30 
weeks. Similar to human T1D, the onset of diabetic symptoms in NOD mice is preceded by 
insulitis, a process defined as a mixed population of leukocyte infiltrating into islets and 
subsequent disruption of islet structure and function. CD4 and CD8 T cells are major “invaders”. 
Normally, the number of CD4 T cells is dominant over CD8 T cells (19, 20). In addition, B cells, 
macrophages, and dendritic cells are also found at the site of infiltration (21).  
 
It was also demonstrated that the disease was able to be transferred in mice by diabetic 
NOD spleen T cells including CD4 and CD8 T cell subsets to the irradiated non-diabetic young 
NOD or NODscid recipients (NODscid mice are immunodeficient because a genetic mutation 
leads to the failure of T cell and B cell development) (22, 23). CD4 T cells are so-called helper T 
cells. They respond to antigens presented by MHC Class II molecules and secrete cytokines such 
as IL-2, IFN-γ, TNF-α, IL-4, IL-10, etc. These cytokines induce further proliferation and/or 
activation of lymphocytes/monocytes. Alternatively, CD4 T cells also express membrane-bound 
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CD40 ligand (CD40L) and Fas ligand (FasL). CD40L triggers the activation of target cells such 
as B cells and macrophages, whereas FasL triggers the apoptosis of Fas-expressing cells. CD8 T 
cells are cytotoxic (or killer) cells. Unlike CD4 T cells, CD8 T cells engage with cells expressing 
specific antigens in the context of the MHC Class I molecule. Once activated, CD8 T cells are 
armed with FasL, perforin and granzyme to kill target cells instead of helping other leukocytes. 
Meanwhile, activated CD8 T cells also secrete IFN-γ and TNF-α/β to sensitize the targets for 
killing machinery equipped by CD8 T cells. Neither the purified CD4 nor the CD8 T cell subset 
from diabetic NOD spleens alone is able to transfer the disease to young NOD or NODscid 
recipients (24). Without the help of CD4 T cells, CD8 T cells from diabetic NOD cannot home to 
islets of NODscid recipients (22). In addition, the disease cannot be transferred by diabetic NOD 
spleen T cells (including CD4 and CD8 T cells) to NODscid recipients that also carry the β2-
microglobulin mutation (25). As the β2-microglobulin mutation leads to a deficiency of MHC 
Class I expression in recipient islet cells, thus they cannot not serve as CD8 T cell targets. 
Therefore, both CD4 and CD8 T cells are required for diabetes development.  Although B cells 
are also observed at the site of islet infiltration, they are generally not considered as primary 
mediators of β-cell destruction. Without T cells, B cells alone cannot induce diabetes in 
NODscid recipients. B cell-depleted diabetic NOD splenocytes transfer disease as well as the 
non-depleted spleen cell population.  The role of B cells in accelerating or postponing the disease 
is mainly achieved by modulating antigen presentation and T cell immunity instead of directly 
targeting the pancreas (26, 27). 
 
The second feature shared by T1D and other autoimmune diseases is that the disease can 
be slowed or prevented by immunosuppressive therapy. Typical chemicals for this therapeutic 
regimen include cyclosporine (28, 29), FK506 (30, 31), steroids (31), and Azathioprine (32). 
They are all immunosuppressive medicines. However, the administration of these agents is 
limited by their toxicity to peripheral tissues, especially kidneys. A promising strategy was 
achieved with the administration of an anti-CD3 monoclonal antibody to block T cell responses 
without toxic effects to other tissues (33). It is noteworthy that all of these regimens are targeting 
T cell activities regardless of T cell antigen specificities. In addition, they are only effective at 
the early stage of the disease progression before the β-cell mass is completely destroyed.  
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A third feature is that the cell-mediated autoimmunity only targets against self-tissues. In 
the scope of T1D, pancreatic β-cells are the ultimate target, whereas glucagon-producing α-cell 
and somatostatin-producing δ-cells are spared. The overt clinical symptom is preceded by 
insulitis. Autoantibodies (secreted by infiltrated B cells with the help of CD4 T cells) (34, 35) 
and self-reactive CD4/CD8 T cells (36, 37) are specific to the β-cell products such as insulin (38-
40), glutamic acid decarboxylase 65 (GAD65) (27, 35, 41, 42) and other β-cell-derived antigens 
(43), which are collectively considered as T1D-related autoantigens. Conceptually, insulitis is 
composed of two phases, concluded from the observation from NOD mice. During the first 
phase, autoantigen-specific naïve CD4 and CD8 T cells are activated in pancreatic lymph nodes 
(PLNs). In the second phase, activated T cells or diabetogenic T cells migrate to the islets and 
specifically kill β-cells. The damage further accelerates lymphocyte infiltration.  
 
In the PLNs, the activation of diabetogenic T cells requires antigen presenting cells 
(APC) – mainly tissue-resident macrophages and dendritic cells (DCs) to present β-cell- derived 
autoantigenic peptides to T cell receptors (TCRs). The initial release of autoantigens is due to the 
physiological β-cell death. Evidence from rodent models has revealed that a wave of 
physiological β-cell death takes place in islets during the juvenile stage, peaking at 14-17 days 
after birth, regardless of normal or diabetes-prone strains (44-47). This wave of β-cell death 
could be due to tissue remodeling during the development, which involves apoptosis (48). 
Alternatively, during the weaning stage, the pancreatic tissue undergoes stress due to massive 
metabolic changes such as the rate of glycogenolysis, gluconeogenesis, lipogenesis and hormone 
production (49). For reasons unknown, β-cells are very sensitive to the stress. Cellular 
components released from dead β-cells are engulfed by APCs, particular DCs, and subsequently 
induce DC maturation. Matured DCs migrate to the PLN. Meanwhile, several critical phenotype 
changes such as upregulation of the antigen processing/presentation machinery and co-
stimulatory expression render matured DCs further competent to activate β-cell-reactive T cells. 
The activation signal not only drives T cells to proliferate, but also induces naïve T cell to 
become armed effector T cells. Naïve CD4 T cells become Th1 or Th2 cells. Naïve CD8 T cells 
become Tc cells.  
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The physiological wave of β-cell death alone is not sufficient to cause diabetes. The 
massive, specific destruction of β-cells is caused by activated T cells that infiltrate into the islets. 
As a part of activation, activated T cells increase the expression of adherent molecules such as 
LFA-1 and ICAM-1, thus enhancing the mobility within tissues. In the islet, activated T cells 
encounter their cognate antigens and manifest their effects. Two major cellular mechanisms are 
involved in T cell mediated β-cell death (50, 51). First, the “cell-cell contact” is the principal 
approach undertaken by self-reactive Tc cells. It is triggered by the engagement between the 
TCRs and the self-peptide:MHC Class I complex on the surface of β-cells. Thus, Tc cells either 
use the Fas/FasL (52, 53) or the perforin/granzyme (54, 55) pathway to induce β-cell apoptosis. 
Activated CD4 T cells, especially Th1 cells, however, manifest their killing effect indirectly. 
Tissue-resident macrophages present islet antigens in the context of MHC Class II molecules and 
induce Th1 cells to secrete cytokines such as IL-2, IFN-γ and TNF-α. IL-2 mainly enhances 
CD4/CD8 T cell proliferation. IFN-γ, on the other hand, not only upregulates MHC, co-
stimulatory molecule expression in the APCs and β-cells that enhance β-cell antigen exposure, 
but also activates macrophages that subsequently secrete soluble mediators to accelerate β-cell 
apoptosis (56). The second mechanism – “soluble mediators” is more complicated and less 
specific than the “cell-cell contact” mechanism since it involves multiple cytokines (IFN-γ, TNF-
α, IL-1, IL-6, and NO) generated by a variety type of cells. Figure 1 briefly illustrates the 
pathways described above.  
2.1.3 Epidemiological statistics 
According to the statistics provided by the National Institute of Diabetes and Digestive 
and Kidney Diseases, by 2005, 20.8 million people in the United States (7 % of the population) 
have diabetes (http://diabetes.niddk.nih.gov/dm/pubs/statistics/index.htm). T1D accounts for 5-
10% of all diagnosed cases of diabetes. Additionally, 13,000 children are diagnosed annually 
with T1D. 
 
Worldwide, the incidence of T1D is varied among different countries, ranging from the 
highest 35/100,000 per year in Finland to the lowest < 0.1/100,000 per year in the People’s 
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Republic of China (57). The enormous geographic variation for the risk to develop T1D is due to 
combined effects of genetic and environmental factors. 
                                                  
 
         
Figure 1. Cellular mechanisms of β-cell death.  
(a). The CD8 T cell is activated by direct recognition of β-cell antigens presented by MHC Class I molecules on the 
surface of the β-cell. Activation induces CD8 T cells to express FasL and perforin/granzymes and trigger β-cell 
apoptosis. (b). Activated CD8 T cells (by direct engagement to the β-cell) and CD4 T cells (recognize β-cell 
antigens presented in the context of MHC Class II complex on the surface of tissue-resident macrophages and other 
APCs) express FasL or membrane-bound TNF-α and trigger β-cell death via FasL/Fas and TNF-α/TNF-R pathways 
(i); activated T cells also secrete cytokines and other soluble death mediators to induce β-cell death directly (ii); 
macrophages are activated by T cells and elicit their cytocoidal activities (iii); the intracellular stress induces the β-
cell endogenous apoptotic pathway (iv) (adapted from reference (57)).   
2.1.4 Genetics of T1D 
The feature of familial clustering is a landmark to determine whether a disorder is an inherited 
disease. The overall risk for developing T1D in North American Caucasian siblings, parents and 
offspring of an individual with T1D varies from 1-15%, as compared to 0.12% in the general 
population (58-63). In addition, twin studies have revealed stronger disease concordance rates 
among monozygotic than dizygotic twins (64). Thus, it is very clear that T1D is a genetically 
associated disorder. However, data from the same study also suggests that T1D is affected by 
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environment factors since the concordance rate for T1D development between monozygotic 
twins is less than 50 %.  
 
According to the information collected by the T1DBase (65), a Type 1 Diabetes specific 
bioinformatics resource founded by the Juvenile Diabetes Research Foundation (JDRF) and the 
Welcome Trust, at least 20  genomic loci have been identified to be associated with the disease 
(Table 1). 
 
The strongest genetic determinant – IDDM1 is located at chromosome 6p21, the Human 
Leukocyte Antigen (HLA) cluster (66), which accounts for over 40 % of the familial clustering 
of T1D (67). This region, approximately 3.5 Mb in length, harbors three different MHC Class I 
α-chain genes – HLA-A, -B, -C, three different sets of MHC Class II α/β-chain genes – HLA-
DP, -DQ, -DR, and genes encoding a variety of antigen processing/presentation related products 
(Figure 2) (1).  
 
 
Figure 2. The organization of human HLA gene cluster. 
The simplified diagram illustrates the location of the genes that encode the α−chain subunits of class I MHC, and 
α/β-chains of class II MHC molecules. Genes shown encode three types of class I proteins (HLA-A, HLA-B and 
HLA-C) and three types of class II MHC proteins (HLA-DP, HLA-DQ, and HLA-DR). An individual can therefore 
make six types of Class I HLA (three encoded by maternal chromosome and three by paternal chromosome) and 
more than six types of class II HLA proteins. The number of class II HLA molecules that can be made is increased 
because 1) there is more than one DR β-chain gene; 2) the DQ, DP β-chains expressed from maternal chromosome 
can pair with the α-chains expressed from either cis-position and trans-position.  (adapted from reference (1)) 
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Table 1. Human T1D gene linkage summary 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
HLA-A, -B, and -C are all polymorphic. Each allele encodes a 44 KDa MHC Class I α-
chain that non-covalently associates with a 12 KDa non-polymorphic β2-microglobulin (Figure 
3A), which is encoded by the β2m gene outside of HLA region. Class I HLA molecules are 
Region name Candidate genes or markers
IDDM1 HLA (DQA1, DQB1, DRB1)
IDDM2 5' INS-VNTR, TH
IDDM3 D15S107
IDDM4 FGF3,D11S1917, MDU1, ZFM1, RT6, ICE, CD3, LRP5
IDDM5 ESR, a046Xa9, MnSOD
IDDM6 D18S487, D18S64, JK 
IDDM7 D2S152, D2S326, GAD1
IDDM8 D6S281, D6S264, D6S446
IDDM9 D3S1303
IDDM10 D10SS193, D10S208, GAD2
IDDM11 D14S67
IDDM12 CTLA-4, CD28
IDDM13 D2S137, D2S164, IGFBP2, IGFBP5
IDDM15 IDDMFYN, D6S283, D6S434, D6S1580
IDDM17 D10S554, D10S592
IDDM18 IDDMIL12B, IL12B
Unnamed Chr1 D1S1617
Unnamed Chr16 IDDMICSBP1, D16S3098
Unnamed Chr8 D8S198
Unnamed ChrX DXS991, DXS999
source: data from T1DBase (http://T1Dbase.org)
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expressed virtually on every nucleated cell surface. Their function is to present intracellular 
antigenic peptides (normally derived from viral products or mis-folded endogenous proteins) to 
CD8 T lymphocytes.  
 
 
 
Figure 3. Class I and Class II MHC molecules. 
(A) The α-chain of a class I molecules has three extracellular domains, α1, α2, α3, encoded by distinct exons. It is 
non-covalently associated with a smaller polypeptide chain, β2-microglubolin, which is not encoded within the 
MHC cluster region. The α3 domain and β2-microglobulin are Ig-like. While β2-microglobulin is monomorphic, 
the α-chain is extremely polymorphic, mainly in the α1 and α2 domains that form the peptide binding site. (B) For 
an MHC class II molecule, both α-chain and β-chain are polymorphic (except α-chain for HLA-DR), mainly in the 
α1 and β1 domains. Meanwhile, α1 and β1 domains form the peptide binding site. The α2 and β2 domains are Ig-
like (adapted from reference (1)).  
 
HLA-DP, -DQ, and -DR molecules consist of two non-covalently associated 
glycoproteins – an approximate 34 KDa α-chain and an approximately 29 KDa β-chain (Figure 
3B). They are expressed on the surface of professional antigen presenting cells (APCs) such as B 
lymphocytes, macrophages, and dendritic cells. Their function is to present engulfed soluble 
extracellular protein antigen fragments to CD4 T lymphocytes. Activated human T cells also 
express Class II HLA (mouse T cells don’t express any MHC Class II molecules). Both the α-
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chain and β-chain of HLA-DP (DPA1, DPB1) and HLA-DQ (DQA1, DQB1) are polymorphic. 
The HLA-DR β-chain gene is polygenic and polymorphic. Several loci within the DR-subregion 
encode functional β-chains to pair with a non-polymorphic α-chain from the DRA1 locus. The 
complexity of human HLA gene organization has evolved to improve the immune recognition 
against a diversified pathogen invasion. Another feature of HLA genomic organization is the 
linkage disequilibrium, particularly between DQB1-DQA1 and DRB1 loci (68). During meiosis, 
the recombination between DQ and DR loci is very rare. The parental DQ-DR haplotypes instead 
of randomly segregated DQA1, DQB1, and DRB1 alleles are stably transmitted to the next 
generation. Therefore, distinct DQ-DR combinations are unevenly distributed in the population. 
In distinct ethnic groups or geographic areas, the frequency of each haplotype is different.  
 
Not all genes within this 3.5 Mb region are genetically associated with T1D. In the early 
stage of familial studies, serological approaches were widely used to determine those common 
HLA haplotypes shared by diabetic parents and children.  Historically, HLA-B8, B15 and B18 
were first observed with increased frequency in T1D patients as compared to a non-diabetic 
control population (69, 70). Then, serological typing for class II HLA loci revealed a stronger 
association between HLA-DR and T1D than the association between HLA-B and T1D (71-73). 
Approximately 95% of T1D patients in most populations have DR3 and/or DR4. Expression of 
HLA-DR2, however, was generally considered to be associated with T1D resistance, and the 
protective effect of DR2 was dominant over DR3 or DR4 alleles. Later on, it was realized that 
serological methods were limited by the availability and the resolution of HLA specific anti-
serums. The advent of molecular biology techniques, especially the Polymerase Chain Reaction 
(PCR) and the DNA sequencing based Sequence Specific Oligonucleotide Probing (SSOP) or 
Single Nucleotide Polymorphism (SNP) increased the resolution of HLA typing and simplified 
the procedure. By analyzing HLA alleles in a variety of racial and ethnic groups, it was revealed 
that the presence of a specific human DQ β-chain polymorphism encoding a neutral amino acid 
(alanine, valine, or serine) other than aspartic acid at the position 57 (so-called non-Asp57β) was 
strongly associated with T1D (4, 5). In contrast, a negatively charged aspartic acid at the position 
57 of the DQ β-chain (Asp57β) appeared to confer “resistance” to T1D progression. The 
association between non-Asp57β DQ allele and T1D is stronger than the HLA-DR3, -DR4. 
Meanwhile, the investigation of the association between the DQ α-chain and the disease 
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suggested that an arginine residue at position 52 of the DQ α-chain was found in high frequency 
in the T1D population (74).  Common non-Asp57β alleles in the Caucasian T1D population 
include DQB1*0302 and DQB1*0201, whereas Asp57β alleles include DQB1*0301 and 
DQB1*0602. Arg52α alleles normally refer to DQA1*0301 and DQA1*0501, whereas non-
Arg52α alleles refer to DQA1*0102, etc. Those haplotypes composed of a non-Asp57β allele 
and an Arg52α allele encode high risk “diabetogenic” heterodimers (7) such as the 
DQB1*0302/DQA1*0301 haplotype (DQ8) and the DQB1*0201/DQA1*0501 haplotype (DQ2). 
The DQB1*0602/DQA1*0102 haplotype (DQ6) is protective. It is noteworthy that DQ8 and 
DQ2 are stably transmitted with DR4 and DR3 to the next generation due to the strong linkage 
disequilibrium between DQ and DR loci. Interestingly, individuals with heterozygosity for 
DR3/DR4 (also heterozygous for DQ8/DQ2) are more susceptible to the disease than a DR3 or 
DR4 homozygote. It has been suggested that individuals with both DQ8 and DQ2 are able to 
produce four different non-Asp57β/Arg52α heterodimer combinations, whereas DQ8 
homozygous or DQ2 homozygous subjects are only able to form one non-asp57β/Arg52α 
heterodimer. In addition, the expression of Asp57β DQ6 confers predominant protection since 
DQ8/DQ6 heterozygous individuals are resistant to the disease. It is consistent with the notion 
mentioned above that the protective effect of DR2 is dominant over susceptible DR3/DR4 
haplotypes because DQ6 is closely linked with DR2. Additional evidence from NOD mice also 
supports the predisposing role of DQ in the progression of T1D, because NOD mice only express 
an H2-Ag7 MHC Class II heterodimer that is regarded as the human HLA-DQ homologue. The 
NOD H2-Ag7 β-chain shares the non-Asp57β feature with HLA-DQ8 β-chain (75). Two amino 
acid mutations from H2-Ag7 β57 serine  aspartic acid and β56 histidine  proline render this 
NOD mutant (NOD.H2-Ag7PD) free from diabetes (76). It is still challenging to pursue whether 
and how DR molecules are also involved in disease predisposition. Although DR molecules are 
not the primary factor in conferring T1D susceptibility, they may play an independent role other 
than DQ in T1D progression. This notion is driven by at least two observations. First, like many 
other autoimmune diseases, all antigen-specific CD4 T cells cloned from peripheral blood of 
T1D patients are exclusively restricted to HLA-DR instead of HLA-DQ (77-79). Second, DQ8-
matched case-control studies demonstrated that the risk for T1D development was modulated by 
the expression of closely linked DR4 (8, 9). It was suggested that different DR4 subtypes might 
be associated with variable degrees of protection. As the HLA-DR molecules are similar to 
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HLA-DQ regarding the structure and the function, DR molecules should manifest their effect 
through influencing CD4 T cell reactivity.  
 
In NOD mice, the MHC gene cluster is also the first reported genetic determinant 
associated with spontaneous diabetes (80). Located on mouse chromosome 17, the cluster 
encompasses genes encoding mouse MHC Class I/II, and other antigen processing/presenting 
related proteins. The unique MHC haplotype in NOD mice, termed H2g7 consists of H2-Kd and 
H2-Db –two MHC Class I α-chain genes, plus H2-Ag7 – MHC Class II α/β-chain genes. NOD 
mice are deficient in H2-E expression due to a deletion in Eα promoter region. H2-Kd and H2-Db 
alleles are also shared by diabetes-resistant strains such as BALB/C and C57BL/6, respectively. 
The α-chain of H2-Ag7 is identical to the α-chain of H2-Ad from BALB/C, however, the β-chain 
of H2-Ag7 in NOD is unique and differs from the β-chain of H2-Ad only at the first external 
domain (75). The NOD H2-Ag7 β-chain contains a histidine at position 56 and a serine at 
position 57, whereas BALB/C H2-Ad β-chain has a proline and an aspartic acid at residues 56-57 
instead. The polymorphism of two residues renders different peptide binding affinity and 
preference. It also confers the H2-Ag7 T1D susceptibility and the H2-Ad T1D resistance. It is 
noteworthy that the non-Asp57β feature of NOD H2-Ag7 is similar to human T1D susceptible 
HLA-DQ8 (DQA1*0301/DQB1*0302) in the Caucasian population. In addition, it is well 
acknowledged that both homozygous expression of the H2-Ag7 and the H2-E deficiency are 
required for spontaneous diabetes development in the NOD. The transgenic expression of H2-Ed 
in NOD background diminishes the diabetes incidence in a dose-dependent pattern (81). The 
mechanism of the protection provided by H2-Ed expression is very complicated and is still under 
investigation.  
 
Another putative genetic predisposing factor of T1D – IDDM2 is briefly illustrated here, 
for it accounts for ~10 % of familial clustering of T1D (82, 83). The IDDM2 refers to the 
variable number of tandem repeats (VNTR) at the 5’-region of human insulin genes. The 5’ INS-
VNTR polymorphisms are categorized into three classes. Class I represents approximate 26-63 
repeats, up to 570 bases in length. Class III represents 140-200 repeats up to 2,200 bases in 
length. Class II is defined as the length between Class I and Class III (84). The VNTR 
polymorphism was demonstrated to influence insulin expression, especially in the thymus (84, 
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85). The protective Class III allele expresses a higher level of insulin than the susceptible Class I 
allele. It has been suggested that high insulin expression in the thymus enhances antigen-driven 
negative selection of insulin-specific autoreactive T cells.  
 
It is noteworthy that neither diabetogenic HLA haplotypes nor alleles are fully 
penetrated, so that not every individual who inherits susceptible haplotypes/alleles from diabetic 
parents will necessarily develop T1D. It actually implies the role of environmental factors in the 
etiology of T1D. 
2.1.5 Environmental factors 
Strong evidence of environmental factors linked to the progression of T1D include the discordant 
disease onset rate between monozygous twins who inherited identical genetic materials from 
their parents (64) and enormous geographic variation of the disease incidence that has been 
observed in world-wide epidemiological studies (86). These differences are not simply due to 
ethnical differences since migrants from countries with low T1D frequency to countries with a 
high frequency are more susceptible to the disease than their compatriots (87).   
 
Viral infection is one of the first etiological hypotheses (88-92). Particular attention has 
been paid to rubella virus and Coxsackie B virus. The involvement of Coxsackie B virus derived 
superantigens in triggering islet specific T cell expansion was identified in severe leukocyte 
infiltrated pancreatic tissues from a child who died from acute-onset T1D related ketoacidosis 
(93). The consumption of cow’s milk or infant formula has also been suspected to be a critical 
environmental trigger or modulator to the progression of T1D. This notion was supported by the 
presence of anti-BSA (bovine serum albumin) antibodies in 100% of subjects affected by T1D 
(94), but it was challenged by the opposite observation (95). In addition, it is also suggested that 
the T1D incidence appears to be influenced by the degree of a society’s cleanliness. The 
“hygiene hypothesis” holds that the improvements in health care delivery and sanitation have 
lead to the rise in autoimmune disorders including T1D (96, 97). Likewise, this hypothesis lacks 
sufficient evidence.  
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In summary, T1D is a degenerative disease. Genetic predisposing factors (susceptible 
HLA haplotypes) are further complicated by a variety of unveiled environmental factors to 
generate autoimmune responses against b-cells and ultimately cause b-cell death. 
2.2 The establishment/maintenance of antigen specificity and self-tolerance 
Although certain HLA/MHC alleles are associated with spontaneous diabetes in human and 
NOD mice, these alleles don’t directly cause β-cell death. Nevertheless, they are responsible for 
the generation of autoreactive T cells and T cell-mediated autoimmunity causes β-cell death. 
2.2.1 The binding between a peptide and an MHC molecule 
Structurally, a peptide:MHC Class II complex exists as a three-chain complex composed of an α-
chain and a β-chain of class II heterodimer plus an antigenic peptide associated with the peptide 
binding groove. Class II molecules without associated to peptides have been previously 
demonstrated to be vulnerable to aggregation and sensitive to proteolytic degradation (98). It 
suggests that the association of class II MHC with a peptide is required for structural integrity 
and stability.  
 
Crystal structure studies have indicated that an MHC Class II heterodimer has two 
membrane-proximal immunoglobulin-like domains within each subunit (α- and β-chain), and a 
membrane-distal peptide-binding site formed by an eight-stranded β-sheet and two α-helical 
regions (Figure 4)(99, 100). The β-sheet acts as the “floor” to provide the support for the bound 
peptide, while two α-helixes act as two “clamps” to hold the bound peptide. Both the α-chain 
and the β-chain are involved in the formation of the binding region. Polymorphic residues in 
each human HLA allele are clustered in the peptide-binding region. They are responsible for the 
peptide binding specificity and affinity. Unlike an MHC Class I molecule, which has closed ends 
at both sides and normally accommodates peptides with 8-10 residues (101-103), an MHC Class 
II heterodimer is open at both sides of the binding region so that there is less restriction to the 
 19 
length of the peptide. The peptide stays in the Class II binding site in a straight extended 
conformation, like a hot dog in a hot dog roll. It has been suspected that this conformation allows 
the most residues of the peptide to be exposed outward, which maximizes the interaction with T 
cell receptor (TCR).  
 
 
 
Figure 4. The illustration of HLA-DR4:Collagen1168-1179 complex crystal structure. 
The peptide binding site formed by the α-chain and the β-chain of HLA-DR4 is simplified as the ribbons in dark 
color and light color, respectively. The peptide of Callagen1168-1179 is fitting in the middle of the DR4 binding site as 
illustrated in a ball-stick style (adapted from PDB file 2SEB with slight modification (101)). 
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Two different types of interaction contribute to the formation of a stable peptide:Class II 
complex – the hydrogen bond interaction and pocket interaction. Hydrogen bonds are formed 
between atoms along the main-chain peptide and side-chains of conserved amino acid residues in 
α-helixes and the β-sheet of the MHC. Therefore, the hydrogen bond interaction is independent 
of peptide sequence. Pocket interactions are formed between side-chains of the bound peptide 
and side-chains of residues in the Class II binding region. The β-sheet “floor” is actually not 
“flat”. Due to the difference in size and direction of side-chains of different residues within the 
“floor” and “clamps”, the surface of the “floor” has several “humps” and several “holes” or 
“pockets”. Apparently, a “pocket” provides more possibility to accommodate a residue with a 
long point-out side-chain than a “hump”.  Normally, a peptide anchors into a Class II binding site 
at 5 principle “pockets” named P1, P4, P6, P7 and P9 according to the position of the residues 
(along the peptide) that interact with the Class II binding site. P1 and P9 locate near the end of 
the binding groove on each side, whereas P4, P6 and P7 cluster in the center of the binding site. 
The pocket interaction is not only determined by the size of the pocket, but also influenced by 
the polarity of the amino acid residues that form the pocket. The amino acid residues within both 
β-sheet “floor” and α-helix “clamps” contribute the polarity and the size of “pockets”. Thus, 
distinct HLA molecules manifest different preferences for peptide binding. The degree of a 
difference is then determined by the similarity of the amino acid sequence along the binding 
groove.  
2.2.2 The structure of TCR – the receptor of peptide:MHC complex 
The nature of hydrogen bonds and pocket interactions allows a single MHC molecule (Class I 
and Class II) to bind a variety of distinct peptides, though the affinity is different (depending on 
peptide sequence and the polymorphisms within the MHC binding groove). An individual 
maximally expresses 6 different Class I and 20 different Class II molecules when he/she carries 
two distinct HLA haplotypes. Any given protein can be degraded into many different fragments 
by proteolytic enzymes in the antigen processing compartment, and in most cases, at least one of 
these peptides is able to bind one or more of MHC molecules and be presented on the surface of 
the cell (104). Thus, the immune system requires a well-tuned recognition system, not only to 
detect all kinds of pathogens, but also to distinguish the foreign from the self so that it avoids 
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eliciting immune responses to self-tissues. One major class of such recognition apparatuses (a 
second category is immunoglobulin that doesn’t interact with HLA) is T cell receptor (TCR), 
which is only expressed on the T cell surface. The antigen recognition is accomplished by the 
TCR/CD3 complex and the co-receptor -- either CD4 or CD8. A TCR/CD3 complex consists of 
two parts – a TCR heterodimer and a CD3 complex (Figure 5), part of which associates with the 
intracellular tail of the TCR. The TCR is only responsible for the antigen recognition. The CD3 
complex converts the TCR:antigen engagement event to the intracellular signals (such as the 
activation of phorsphotyrosine kinases, the cleavage of phosphatidylinositol (PIP2), calcium 
flux, etc), which ultimately induce T cell activation. CD4+ T cells recognize antigenic peptides 
presented by MHC Class II complexes, whereas CD8+ T cells recognize antigenic peptides in the 
context of MHC Class I molecules. The co-receptor CD4 and CD8 are also involved in antigen 
recognition by directly interacting with the non-polymorphic portion of the MHC molecules 
(Figure 6) (105, 106). Both CD4 and CD8 are believed to transduce signals independently from 
CD3 complex (107, 108). 
 
 
                                                       
 
 
Figure 5. The TCR and its associated CD3 complex. 
The TCR heterodimer is composed of two transmembrane glycoprotein chains, α- and β-chain. Both α- and β-chain 
have large external domains and small cytoplasmic tails that associate with four other polypeptides, collectively 
called CD3 complex. (Adapted from reference (1)) 
 
 22 
                                                        
 
Figure 6. CD4 and CD8 co-receptors on the surface of T cells. 
TC cells express CD8, which interacts with the MHC Class I complex, whereas TH cells express CD4, which 
interacts with MHC Class II proteins. It is noted that co-receptors bind to the same MHC protein that the TCR has 
engaged, so that they are brought together with TCRs during the antigen recognition process. Whereas the TCR 
binds to the variable part of the MHC protein that form the peptide binding groove, the co-receptor binds to the 
invariant part, far away from the MHC peptide binding groove (Adapted from reference (1)). 
 
                                                       
 
 
Figure 7. Schematic diagram to illustrate that the TCR is composed of an α- and a β-chain. 
Each chain is about 280 amino acids long and has a large extracellular portion that is folded into two Ig-like 
domains – one variable (V) and one constant (C). The antigen binding site is formed by a Vα and a Vβ domain, thus 
each TCR heterodimer has one binding site for antigen engagement. The α-chain and the β-chain are covalently 
associated to each other through a disulfide bond. A T cell typically has about 30,000 such receptors on its surface. 
(Adapted from the reference (1)) 
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Most T cells express αβTCRs that consist of an α-chain and a β-chain. Only a small 
subset of T cells express γδTCRs.  External portions of TCR α- and β-chains have two domains 
– a variable domain and a constant domain, respectively (Figure 7). Variable domains from α-
chain and β-chain together form the antigen recognition site, which directly interacts with the 
combination structure of the antigenic peptide:MHC complex.  
 
Figure 8. The organization of mouse TCR α-/β-chain genes.  
In the mouse, the α-chain cluster consists of 70-80 V-segments categorized into 13 subfamilies (defined as groups of 
V gene segments that share greater than 75 % nucleotide sequence homology), though some of them are not 
functional (Pseudo-gene). Each functional V-segment contains a promoter, one exon encoding a leading sequence 
and one exon encoding the V-region. A cluster of ~60 J-segments is located a considerable distance from the V-
segment cluster. The J-segment cluster is then followed by a single constant-domain gene. The α-chain gene cluster 
is actually interrupted between the J and V-segment loci by another TCR gene cluster – the δ-chain cluster (not 
shown here) The β-chain gene cluster is located on a different chromosome and the organization is slightly different. 
About 50 functional V-segments out of 17 subfamilies are located distantly from two separate clusters that each is 
composed of a single D gene segment, together with 6 or 7 J gene segments and a single constant-region gene. The 
two Cβ genes are very similar to each other. (Adapted from reference (109)) 
 
The genomic organization of TCR α-/β-chain genes, however, is extremely complicated 
(Figure 8). Both the α-chain and the β-chain are encoded by genes constructed by rearrangement 
of discontinuous germline TCR gene segments for variable (V), diverse (D) (only existing in β-
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chain), joining (J), and constant (C) regions (Figure 9). The rearrangement is catalyzed by DNA 
recombinases that are encoded by the recombinant activity genes –RAG1 and RAG2. Products of  
 
Figure 9. TCR α-/β-chain gene rearrangement and expression. 
Both α-/β-chain genes are composed of discrete segments that are joined by somatic recombination during 
development of the T cell in the thymus. For the α-chain, a Vα gene segment joins to a Jα gene segment to create a 
functional exon. Transcription and splicing of the VαJα exon to Cα generates the mRNA that is translated to yield the 
T cell receptor α-chain polypeptide. For the β-chain, the variable domain is encoded in three gene segments, Vβ, Dβ, 
and Jβ. Rearrangement of these gene segments generates a functional VβDβJβ exon that is transcribed and spliced to 
join to Cβ. The resulting mRNA is translated to yield the T cell receptor β-chain. The α- and β-chain pair to each 
other to generate a functional TCR (Adapted from reference (110)). 
 
the RAG-1/2 recognize specific recombination signaling sequences flanking each individual 
TCR gene V, (D), J segment and bring them together during particular periods of T cell 
development. Each rearrangement is believed to be an independent event so that the V(D)J 
recombination is individually randomized and collectively creates all possibilities of V(D)JC 
rearrangements among a whole T cell population. Additional diversities of rearrangement are 
also obtained at the V-(D)-J joint by the random introduction of nucleotides not encoded in the 
 25 
germline, or deletion of nucleotides encoded in the germline. Theoretically, the total diversity of 
T cell receptors is about 1016. It ensures that all possible peptide:MHC complexes can be 
recognized by one or some TCRs, as long as the affinity between the TCR and its ligand 
achieves a threshold. It is very likely that the generation of such a huge size TCR repertoire has 
co-evolved with the MHC system to form a comprehensive recognition system and provide the 
host with a mighty defense system against the invasion of all possible foreign pathogens. 
2.2.3 T cell maturation and central tolerance 
All T cells are developed from bone marrow pluripotent hematopoietic stem cells that do not 
express TCRs. In the thymus, with special intercellular signaling, these bone marrow-derived 
precursors then differentiate into thymocytes expressing TCRs. Therefore, the T cell 
development is actually the process of TCR repertoire generation. Three events are critical to T 
cell ontogeny: 1) the up-/down-regulation of RAG expression and the germline DNA 
rearrangement of TCR α-/β-chain genes; 2) the expression of co-receptor CD4/CD8 and lineage 
commitment; 3) thymic selection and central tolerance establishment. 
 
The differentiation starts from the expansion of precursor cells to form the population of 
CD4-CD8- double negative thymocytes (DN). The expression of RAG-1/2 is upregulated very 
briefly in a subset of DN thymocytes. At the DN stage, only β-chain gene rearrangement occurs 
(110). The rearrangement starts from one chromosome. Once a productive rearrangement is 
achieved, that β-chain then pairs with a surrogate α-chain –pTα to form a preTCR, which has 
been demonstrated to prevent further β-chain rearrangement from the second chromosome (111). 
If first rearrangement fails to generate a functional β-chain polypeptide because of the non-sense 
mutation introduced by randomly inserting or deleting nucleotides, the process continued 
allowing a second rearrangement from other chromosome. If both rearrangements fail to 
generate a functional β-chain to form a preTCR, the thymocyte clone is unable to receive 
survival signals and undergoes apoptosis. The allelic exclusion of further rearrangement is 
known as “β-selection” and allows each T cell to express a single TCR β-chain. A successful “β-
selection” renders the thymocytes transition from DN into CD4+CD8+ double positive (DP) 
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thymocytes. At this stage, RAG-1/2 expression is activated again and allows rearrangement of α-
chain gene elements. The allelic exclusion of the α-chain is not strictly enforced since two 
distinct TCR α-chains have been detected in T cell clones and hybridomas, though in most cases 
only one αβ heterodimer renders antigen specificity (112, 113). The functional α-chain then 
pairs with a previously matured β-chain to form a mature TCR heterodimer and translocates to 
the cell surface, where they are engaged with self-peptide:MHC complexes expressed on the 
surface of thymic cortical epithelia and undergo a process termed positive selection. Only the DP 
thymocytes bearing TCRs with enough avidity to self-peptide:MHC complex can survive. It is 
noted that the avidity is not only determined by the affinity of the interaction between a single 
TCR and its ligand, but also determined by the density of TCR:peptide:MHC engagements 
between the thymocytes and antigen presenting cells (114). Most DP thymocytes fail to be 
positively selected due to the weak interaction between TCR and self-MHC and undergo 
apoptosis. Therefore, the positive selection generates a TCR repertoire restricted by self-MHC 
and consequently ensures that all TCRs are able to detect foreign pathogens presented only in the 
context of self-MHC molecules. The successful positive selection also down-regulates RAG 
expression to prevent further α-chain rearrangement. Meanwhile, the lineage commitment is 
determined as DP thymocytes transit into a CD4 or CD8 single positive thymocyte stage (SP). 
The mechanism of CD4 and CD8 commitment is still not clear.  Prior to obtaining full 
maturation and entering the periphery for immune surveillance, SP thymocytes encounter 
another checkpoint – the negative selection. Those SP thymocytes that bear TCRs interacting 
with self-peptide:MHC complex with high avidity are deleted from the repertoire. Thus, clonal 
deletion ensures that matured T cells are not able to recognize self-antigen in the periphery and 
protect self-tissue from autoimmune attack. Apparently, the negative selection is also self-
peptide:MHC dependent. It occurs mainly at the thymic medulla, apart from the compartment for 
positive selection. Therefore, the intercellular signals are very different.  
 
Theoretically, the size of the TCR repertoire can be as great as 1016 (1, 109). However, 
positive and negative selections dramatically reduce the size. Positive selection only allows 
thymocytes bearing “useful” TCRs (self-MHC restricted) to survive. Negative selection removes 
the thymocytes bearing “harmful” TCRs (reactive to self-peptide) from the repertoire and 
establishes central tolerance. The efficiency of negative selection is affected by several factors.  
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1) As negative selection is to delete thymocytes that recognize self-antigens, the 
expression of self-antigen in the thymus is required and the degree of expression may generate 
very different outcomes. In addition to the report that the risk to develop diabetes is weakly 
associated with the relative expression level of insulin in the thymus (82-85), recent studies of 
the aire gene provide substantial evidence regarding the association between thymic expression 
of self-antigen and the efficiency of negative selection. Aire is a transcription factor specifically 
expressed in thymic medullary epithelial cells (MECs) – the same cell population directing 
negative selection. Aire-deficient MECs have diminished expression of peripheral tissue-specific 
genes (115, 116), and Aire-deficient mice develop multi-organ autoimmune responses (115, 
117), which indicate the complete loss of self-tolerance. In addition, in a study using hen-egg-
lysosome (HEL)-specific TCR transgenic mice in conjunction with transgenic expression of 
HEL under the control of an insulin promoter, it was found that thymocytes were deleted in the 
presence of Aire, whereas they failed to be deleted in the absence of Aire (118).  
 
2) As negative selection is TCR engagement dependent, the stability of the TCR ligand 
can also affect the efficiency of negative selection. Structural studies have showed that the 
presence of a non-Asp57b is shared by human T1D susceptible HLA-DQ8/DQ2 and the mouse 
spontaneous diabetes susceptible gene H2-Ag7. It distinguishes them from other diabetes resistant 
alleles such as HLA-DQ6 in humans and H2-Ad in mice, which have an aspartic acid residue at 
the position 57 of HLA/MHC Class II b-chain. It has been noticed that the non-Asp57b confers 
the predisposing HLA/MHC Class II molecules a unique P9 structure (119). The presence of 
aspartic acid at the position 57 in disease resistant alleles allows the formation of a salt-bridge – 
two hydrogen bonds between the Asp57b side-chain and the Arg76a side-chain. However, in the 
HLA-DQ8/DQ2 or H2-Ag7, the aspartic acid is replaced by an alanine residue that has a non-
polar side-chain. Therefore, different from most Asp57b heterodimers, DQ8/DQ2 and H2-Ag7 
fail to form the salt-bridge with the arginine residue at the a-chain position 76 and thus leave a 
big open P9 pocket at the end of the peptide-binding groove. This unique feature disenables non-
Asp57b alleles to bind a peptide with high affinity and is associated with impaired negative 
selection (120).  Consequently, more thymocytes bearing self-reactive TCRs pass the checkpoint 
and enter the periphery. Once they re-encounter cognate peptides derived from tissue-specific 
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antigens, autoimmune responses will occur.  The contrasting outcome of the non-Asp57b vs. 
Asp57b has been strongly supported by the observation of a reduced incidence of spontaneous 
diabetes in NOD mice transgenically expressing mutated H2-Ag7 (Ser->Asp57) instead of wild 
type H2-Ag7 (121). In addition, studies using HLA transgenic mice (devoid of murine 
endogenous MHC Class II but expressing co-stimulatory molecule B7.1 in the b-cells) also 
demonstrated that the expression of non-Asp57b HLA-DQ8 led to the progression of insulitis 
and spontaneous diabetes while the expression of Asp57b HLA-DQ6 inhibited the lymphocytes 
infiltration to islets and abolished the onset of diabetes (122). 
2.2.4 T cell activation and peripheral tolerance 
Mature SP thymocytes, so-called naïve T cells, leave the thymus and enter the periphery for 
immune surveillance. They circulate between peripheral blood and secondary lymph organs until 
they encounter antigens. Upon antigen engagement, they are activated and manifest their effects 
such as clonal expansion, cytokine secretion and/or cell-mediated cytotoxicity. The lymph node 
is the venue where T cell activation occurs. At least three checkpoints are required for T cell 
activation (123). The first checkpoint is the cell-cell contact, which is mostly provided by 
intergrins expressed by both T cells and antigen presenting cells (APCs). The second checkpoint 
is the engagement of peptide:MHC complex to the TCR.  The co-receptor (CD4 or CD8) is also 
involved in the engagement and independently transduces signals that eventually merge with 
signals from TCR/CD3 complex. It is noteworthy that the T cell and the APC are brought close 
enough by adhesion molecules so that the TCR has a chance to find its ligand, however, the 
outcome is affinity dependent. Every mature T cell has one rearranged β-chain gene and at most 
two rearranged α-chain genes. Thus, most T cells have only one kind of TCR on their surface 
while some may have two kinds with different a-chains. The numerous T cells matured from the 
thymus thus represent a huge TCR repertoire. From within, only a very limited number of TCRs 
(or T cells bearing these TCRs) are able to interact with a specific peptide:MHC complex with an 
affinity that is high enough to reach a threshold and initiate signal transduction. Presumably, this 
process starts from a few TCR molecules and few peptide:MHC complexes. It induces events 
such as tyrosine phosphorylation, cytoplasmic Ca++ flux, which is required to redirect 
cytoskeleton organization toward the site of engagement to facilitate the recruitment of more 
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TCR/CD3 complexes and accessory molecules to the spot of initial contact. The last checkpoint 
is the maintenance of a stable contact synapse, which is the fundamental signaling unit to reach a 
full activation. It depends heavily on the number of TCR ligands on the surface of the APC to 
maintain the TCR/CD3 complex clustering on the surface of the T cell and constant signaling 
transduction. This is a positive feedback or self-strengthening system because increasing TCR 
engagements continuously bring more and more TCR/CD3 complexes to the site where T cell 
interact with the APC and stabilize the TCR:peptide:MHC synapse (surrounding accessory 
molecules are also included in the synapse structure). Hence, the T cell will have enough time to 
transduce the signal constantly to the nucleus to accomplish activation-associated gene 
transcription. It has been estimated that ~8,000 TCRs are required to be engaged to achieve a 
successful activation in the absence of co-stimulation (CD28-CD80 interaction)(124). Even with 
the co-stimulation, ~2,000 TCRs are still required. 
 
The first checkpoint implies a pre-inflammatory condition in the LN so that increased 
cell-cell contact is feasible due the upregulation of adhesion molecules under that condition. The 
second checkpoint requires an initial antigen exposure and the availability of T cell recognition. 
The third checkpoint demands the abundance of both antigens and MHC molecules. Not 
fulfilling any of these checkpoints leads to non-signaling or partial signaling, and the naïve T cell 
stays in resting or anergic status. It actually provides the premise for peripheral tolerance, which 
is a complementary mechanism to thymic negative selection (so-called central tolerance) in 
preventing autoimmunity.  
 
During negative selection, most thymocytes bearing self-reactive TCRs are deleted to 
avoid comprehensive autoimmune activities. This event depends on the presentation of self-
peptides derived from peripheral self-proteins expressed in the thymus. Although a large scope 
of peripheral tissue proteins are expressed in MECs under the control of Aire (115), certain 
tissue-specific self-proteins may still not be expressed or only expressed at very low levels. It is 
possible to allow a certain number of thymocytes bearing potentially self-reactive TCRs to 
escape deletion and enter the periphery. In addition, as just mentioned, there are defects in the 
establishment of central tolerance with the expression of certain MHCs (such as HLA-DQ8, DQ2 
in human and H2-Ag7 in mouse) and many autoreactive T cells escape deletion. In fact, some 
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evidence indicated that autoreactive T cells existed even in the periphery of healthy individuals 
and non-autoimmune-prone experimental animals (125, 126). However, they have to be fully 
activated prior to breaking self-tolerance and causing tissue damage (127, 128). In a normal 
physiological condition (a non-inflammatory situation, no foreign pathogen infiltration), 
peripheral tissue cells (endothelia) and antigen presenting cells express a low level of adhesion 
molecules, MHC molecules, and co-stimulation molecules. Most autoreactive T cells, if not all, 
fail to be activated either because they can’t access the targets without the help of adhesion 
molecules or because they are not able to form stable TCR:peptide:MHC synapses without the 
help of co-stimulation (129) and enough autoantigens. It should be noted that the inflammation 
caused by pathogen invasion possibly facilitates the breakage of peripheral tolerance in a 
bystander style. Normal anti-pathogen immune responses induce the secretion of inflammatory 
cytokines such as IFN-γ and TNF-α. Both of these upregulate the expression of adhesion 
molecules and antigen processing/presenting machineries in APCs. On the other hand, anti-
pathogen responses inevitably cause tissue damage and increase the release of self-proteins that 
might be taken up by APCs and act as autoantigens for autoreactive T cells. Since it takes time 
for the immune system to clear the invasion of pathogens, the exposure of self-proteins persists 
to an extent that is sufficient to activate autoreactive T cells. 
 
Another important peripheral tolerance realm is contributed by naturally occurring T 
regulatory cells (Treg) (130, 131). Like other CD4 T cells, Treg cells mature in the thymus. Unlike 
other CD4 T cells, they constitutively express CD25, the α-chain of the IL-2 receptor, which 
normally is not expressed in naïve CD4 T cells until they are activated (132). Treg cells express 
diverse αβTCR. The specificity of Treg cells is mysterious. It has been suggested that they are 
likely to be reactive to self-peptides with a relatively high avidity (133). The importance of Treg 
in maintaining self-tolerance has been demonstrated by the severe autoimmunity in foxp3-
deficient mice and human individuals with a nonsense mutation in the foxp3 gene (134-136). The 
foxp3 gene encodes a transcription factor specifically expressed in the CD4+CD25+ Treg 
population and it has been demonstrated to be the master gene directing the development and the 
function of Treg cells (137, 138). The TCR engagement is required for the induction of foxp3 
expression and Treg cell lineage commitment in the thymus. However, the details bridging the 
TCR signal and Treg cell maturation are still missing. Treg cells dominantly suppress other T cell 
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responses by mechanisms that have not been completely understood. Both inhibitory cytokine 
secretion (IL-10, TGF-β) and cell-cell contact (CTLA-4, mTGF-β) might be involved (132, 139-
142). In addition, it has also been suggested that Treg cells not only inhibit IL-2 secretion by 
effector cells but also compete for IL-2 with other effector cells so that the expansion of those 
effector cells is diminished (143-145). 
2.3 DQ8 and DR4 
As mentioned in the previous section of Genetics of T1D, DQ8 has been identified as the major 
genetic determinant associated with T1D (4, 5). Results from crystal structure studies also 
provide fundamental evidence that DQ8 differs from other T1D resistant alleles (such as DQ6) at 
the structure of the binding groove (119). This structural feature confers DQ8 less capable of 
deleting autoreactive T cells during negative selection than other protective DQ alleles. The data 
from HLA-DQ8 vs. DQ6 transgenic mouse models confirms that DQ8 is responsible for the 
break of central tolerance to β-cell antigens (122).  
 
However, it is not crystal clear how HLA-DR is also involved in disease progression, 
either independently from DQ8 or in conjunction with DQ8. The structure of HLA-DR4 
(DRB1*0401) doesn’t reveal the defect that could be responsible for inefficient negative 
selection. Previous genetic studies suggested that the high frequency of DR4 in Caucasian T1D 
population was due to the strong linkage disequilibrium between DR loci and DQ loci. However, 
other results from DQ8-matched case-control studies indicated that different DQ8-DRB1*04 
haplotypes were associated with variable risk to develop T1D, depending on which DRB1*04 
allele was carried by the haplotype (8, 146). It suggested that different DR4 subtypes provide 
variable degrees of protection to disease onset, in the order of 
DRB1*0405<0402<0401<0404<0403, 0406. Briefly, DQ8-DRB1*0403 and DQ8-DRB1*0406 
provide strong resistance, whereas DQ8-DRB1*0405, 0402, 0401 confer susceptibility and DQ8-
DRB1*0404 is a neutral haplotype.  The role of the DR4 allele was further highlighted by a 
result using HLA-DQ8/DR4 transgenic mice (10). With transgenic expression of the co-
stimulatory molecule B7.1 in β-cells, 75 % of HLA-DQ8 transgenic mice developed spontaneous 
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diabetes incidence, whereas only 25 % of HLA-DQ8DR4 (DR4 co-expression) transgenic mice 
became diabetic. This suggested that DR4 (0401) had a certain regulatory role to the disease 
susceptibility conferred by DQ8, though DQ8-DRB1*0401 was defined as a high risk haplotype. 
In another study, H2-E transgenic NOD mice were protected from disease in a dose-dependent 
manner (81). An interesting observation from this study was that H2-E expression didn’t account 
for clonal deletion of autoreactive T cells since the continuous presence of H2-E expression in 
the periphery was required to keep the animal free from diabetes in bone marrow transferring 
experiments. 
 
Therefore, the involvement of DR4 alleles in the progression of T1D is not as simple as a 
linkage mark to susceptible DQ8.  
 
Structurally, DR4 and DQ8 are similar. The first domain of HLA-DR4 α/β-chains 
associate together to form the peptide binding site as well as any other DQ molecule does. 
Functionally, just like the DQ8 molecule, DR4 is also responsible for presenting peptides to CD4 
T cells. As for biosynthesis, DQ and DR also share many similarities. They are restrictedly 
expressed in antigen presenting cells (APCs) such as B cells, macrophages and dendritic cells 
(human activated T cells also express MHC Class II). The cell-specific expression pattern is 
controlled at the transcription level by the transactivator CIITA that is constitutively expressed in 
APCs (147). The α/β-chain of DQ or DR are transcribed and translated independently. The 
assembly of DQ and DR heterodimers occurs in the lumen of the endoplasmic reticulum. For 
both DQ and DR, a newly assembled heterodimer must avoid clogging their peptide binding 
groove prematurely with peptides derived from endogenously synthesized proteins in the ER 
lumen. A special polypeptide – invariant chain (Ii) ensures this by associating with heterodimer’s 
peptide binding groove by a fragment spanning amino acid residues from 89-104 along the Ii 
(148). This fragment, also called MHC Class II-associated invariant chain peptide or CLIP, 
blocks the peptide-binding groove from binding other peptides in the lumen of the ER. Three 
αβIi complexes then associate with each other to the C-terminal fragment of Ii to form a 
complex that actually consists of 9 polypeptides. The complex is subsequently translocated from 
the ER to the trans-Golgi network, then to a late endosomal compartment (Figure 10). Here, the 
invariant chain is cleaved by proteases, leaving CLIP alone still in the peptide-binding groove of 
the MHC protein. Another molecular chaperon -- HLA-DM (H2-M in mice) facilitates the 
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release of CLIP and the uploading of peptides derived from endocytosed exogenous soluble 
proteins to the Class II peptide binding site. The peptide:Class II MHC complex is then 
translocated from the endosomal compartment to the cell surface. 
Figure 10. The biosynthesis of an MHC Class II molecule and the processing of an extracellular protein 
antigen for presentation to a helper T cell. 
This cartoon illustrates a newly synthesized MHC Class II heterodimer that associates with an Ii and translocates 
from the lumen of the ER through trans-Golgi network to the late endosome, where Iis are degraded and replaced by 
antigenic peptide derived from extracellular proteins that are taken up by the cell through endocytosis. Matured 
peptide:MHC Class II complexes then translocate to the cell membrane and are ready to engage T cells (adapted 
from reference (1)) 
 
As DR4 shares similarities with DQ8 regarding their structure, function and biosynthesis, 
they are thus potentially capable of binding to the same peptide. This promiscuous binding 
activity was experimentally demonstrated by the evidence that peptides derived from a 
Mycobacterium tuberculosis antigen were found to be bound with multiple HLA alleles 
including HLA-DR4 (DRB1*0401) and HLA-DQ8 (DQA1*0301/DQB1*0302) (149).  
Additionally, peptide binding assays in cell-free conditions also indicated that several peptides 
derived from the T1D related autoantigen, GAD65, were capable of binding DQ8 and DR4 
(150).  
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A unified peptide competition model has been proposed to address a possible mechanism 
for the DR4-directed (or H2-E-mediated in the H2-E transgenic NOD mouse model mentioned 
early) peripheral tolerance that may provide an explanation for the role of DR4 and variable 
degrees of protection conferred by distinct DR4 subtypes (11). It hypothesizes that the protection 
is due to the co-expression of DR4 alleles manifesting stronger peptide binding affinity than T1D 
susceptible DQ8 molecules. The premise of the competition is that HLA-DQ8 and HLA-DR4 are 
able to bind the same diabetogenic peptides (though it is not necessary to use identical anchoring 
residues from target peptides). As a consequence of the competition, the abundance of self-
peptide:DQ8 complex on the surface of antigen presenting cells is lower than in the situation 
where there is no strong competitor. Thus, the corresponding T cell response is diminished since 
the number of TCRs engaged by peptide:DQ8 complex may be decreased proportionally (151). 
Alternatively, an increased antigenic peptide concentration is required as compensation. Hence, 
the risk to develop T1D is increased when a diabetogenic peptide (derived from islet antigens 
such as insulin or GAD65) prefers binding with DQ8 better than other DQ or DR molecules. In 
contrast, when DQ8 is co-expressed with a DR manifesting strong peptide binding affinity, the 
chance of the binding between DQ8 and peptide is reduced.  
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3.0  MATERIALS AND METHODS 
3.1 Animals 
B6.129-H2dlAb1-Ea/J (The Jackson Laboratory, Bar Harbor, ME) 
HLA-DQ8 and HLA-DR4 transgenic mice (courtesy of Dr. Li Wen, Yale University) 
 
The animals were housed and bred under pathogen-free conditions in the Animal Facility of the 
Rangos Research Center at the Children’s Hospital of Pittsburgh. The usage for generating HLA-
DQ8 transgenic mice for antigen-specific CD4 T cell lines was approved by the Children’s 
Hospital of Pittsburgh Animal Research and Care Committee (ARCC) protocol #16-03. The 
usage of HLA-DQ8/DR4 transgenic mice and MHC Class II deficient C57BL/6 mice was 
approved by the ARCC protocol #25-04. 
3.2 Immunofluorescence staining for flow cytometry analysis or cell sorting 
Materials 
FACS Staining buffer 
1 x PBS, pH7.4 (Gibco/Invitrogen, Carlsbad, CA) 
0.1 % Na3N (w/v) (Sigma, St. Louis, MO) 
1 % BSA (w/v) (Sigma, St. Louis, MO) 
FACS Fixation buffer 
1 x PBS, pH7.4  
1 % Paraformaldehyde (w/v) (Sigma, St. Louis, MO) 
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Fluorescence-conjugated mAbs and isotype controls  
5-ml polystyrene tubes (Cardinal Health, McGraw Park, IL) 
Glass Pasteur Pipette (Cardinal Health, McGraw Park, IL) 
Sorvall RT7-plus, Centrifuge (Newtown, CT) 
BD FACSCalibur Flow Cytometer (Becton Dickinson, Palo Alto, CA) 
BD FACSVantage SE DIVA Cell Sorter (Becton Dickinson, Palo Alto, CA) 
 
1) Typically, 5 x 105 cells are required for staining process for a regular flow cytometry 
analysis to inspect the expression of a surface marker.* 
2) Centrifuge 1,000 rpm x 10 minutes at room temperature.  
3) Resuspend the cell pellet in 50 ul of FACS staining buffer and add 10 ul antibody with 
proper dilution, vortex for 5 seconds. 
4) Incubate the cell suspension on ice for 30 minutes, protect from light. 
5) Add 2 ml FACS staining buffer to wash the cells. 
6) Centrifuge at 1,000 rpm x 10 minutes at room temperature. 
7) Repeat step 5) and 6) once.  
8) Resuspend the cell pellet in 500 ul FACS fixation buffer. ** 
9) Analyze staining results with a flow cytometry. 
 
*For cell sorting to separate distinct cell subpopulations according to surface marker 
expression, the amount of reagents (such as buffer, and antibodies) needs to be adjusted 
proportionally.  
**For cell sorting experiment, use the staining buffer instead of the fixation buffer to resuspend 
the cell pellet prior to applying the sample to the cell sorter. 
3.3 Transgenic mice HLA genotyping 
Materials 
Weanling mice (3-week old) required for genotyping 
Heparinized microhematocrit tube (Fisher Scientific, Pittsburgh, PA)  
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0.9 % Saline, 1 mM EDTA (Sigma, St. Louis. MO) 
Red blood cell lysis buffer (Sigma, St. Louis, MO) 
FACS staining buffer and fixation buffer  
FITC-conjugated anti-HLA-DQ mAb, Leu-10; PE-conjugated anti-HLA-DR mAb, L243; APC-
conjugated rat anti-mouse CD45R/B220 mAb, RA3-6B2; purified anti-mouse CD16/CD32 
antibody (mouse Fc blockade), 2.4G2; isotype control antibodies (BD/Pharmingen, San Diego, 
CA) 
5-ml polystyrene tubes 
Glass Pasteur pipettes 
Centrifuge 
BD FACSCalibur Flow Cytometer 
 
1). Manually restrain the animal (as illustrated in Figure 11). Introduce the end of the 
microhematocrit tube at the medial canthus of the orbit. Carefully advance the tip of the 
microhematocrit tube gently towards the rear of the socket until blood (~200 ul) flows into the 
tube. Discharge the blood into a 5-ml polystyrene tube containing 2 ml of 0.9 % saline-EDTA 
solution. Dab excess blood from the site with a clean tissue paper. Place the tube on ice while 
collecting blood from other animals. 
Figure 11. Collect peripheral blood from a weanling mouse (152). 
 
2). Centrifuge the blood suspension, 1,000 rpm x 5 minutes at 4 °C. Aspirate the solution 
carefully without disturbing the cell pellet, resuspend the cell pellet in 1 ml of red blood cell lysis 
buffer and incubator the suspension for 5 minutes at room temperature. 
3). Repeat step 2 once. 
 38 
4). Centrifuge, 1,000 rpm x 5 minutes at 4 °C. Add 10 ul of purified anti-mouse 
CD16/CD32 antibody to block Fc receptors expressing on white blood cell surface. Incubate the 
suspension at room temperature for 15 minutes. 
5). Stain the cell suspension with fluorescence-conjugated anti-HLA mAb(s), and anti-
mouse CD45R/B220 mAb. 
6). Flow cytometry analysis to examine mAb staining results. 
3.4 Prepare single cell suspension from mouse lymph nodes, spleen, and thymus 
Materials: 
Mice with identified transgenic HLA genotype 
Red blood cell lysis buffer 
10 % FBS (v/v)-supplemented DMEM completed Medium, 0.22 um filter sterilization 
DMEM medium, high glucose (Invitrogen, Carlsbad, CA) 
10 % heat-inactivated fetal bovine serum (FBS) (Invitrogen, Carlsbad, CA) 
2 mM L-glutamine (Invitrogen, Carlsbad, CA) 
5 mM HEPES buffer (Invitrogen, Carlsbad, CA) 
1 mM non-essential amino acid solution (Invitrogen, Carlsbad, CA) 
1 mM Sodium Pyruvate (Invitrogen, Carlsbad, CA) 
100 U/ml Penicillin, 100 ug/ml Streptomycin (Invitrogen, Carlsbad, CA) 
50 uM β-mercaptoethanol (Sigma, St Louis, MO) 
2 % NMS (v/v)-supplemented DMEM complete medium, 0.22 um filter sterilization 
DMEM medium, high glucose 
2 % Normal mouse serum (NMS) (Cedarlane, Westbury, NY) 
2 mM L-Glutamine 
5 mM HEPES buffer 
1 mM non-essential amino acid solution 
1 mM Sodium Pyruvate 
100 U/ml Penicillin, 100 ug/ml Streptomycin 
50 uM β-mercaptoethanol 
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70 % Ethanol 
Trypan-blue (Sigma, St. Louis. MO) 
Scissors and forceps (Cardinal Health, McGaw Park, IL), autoclave sterilization 
Glass homogenizer (Cardinal Health, McGaw Park, IL), autoclave sterilization 
Hemocytometer (Fisher Scientific, Pittsburgh, PA) 
50-mL conical tubes (Cardinal Health, McGaw Park, IL) 
Cell restrainer, 40 um (Cardinal Health, McGaw Park, IL) 
250-ml and 500-ml Filter unit, 0.22 um (Cardinal Health, McGaw Park, IL) 
Centrifuge 
Inverted and upright microscopes 
 
1). Mice were euthanized through CO2 inhalation followed by cervical dislocation.  
Figure 12. Illustration of mouse lymph organs. 
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2). In a bio-safety hood, lay the mouse on a clean blue pad. Rinse the abdomen with 70 % 
ethanol. Make a “V” shape incision on the abdomen with scissors, carefully remove the lymph 
nodes, spleen or thymus with a sterile set of forceps and scissors. The illustration of mouse 
lymph organs (except for bone marrow) is shown in Figure 12. 
3). Keep the tissue(s) in ice-cold DMEM complete medium (For primary in vitro T cell 
culture, use 2 % NMS DMEM medium rather than 10 % FBS DMEM medium to avoid non-
specific T cell responses. For other applications, such as preparing antigen presenting cells for 
restimulation, or preparing thymocytes as feeder cells for T hybridoma generation, use 10-20 % 
FBS DMEM medium) 
4). Pour the tissue(s) and 5 ml medium into a glass homogenizer, grind the tissue(s) into a 
single cell suspension, then the single cell suspension is transferred from the homogenizer 
through a cell strainer to a 50-ml conical tube. Wash the homogenizer with 5 ml medium once, 
and transfer the washing medium to the 50 ml conical tube. Centrifuge, 1,000 rpm x 5 minutes,  
5). Carefully aspirate the liquid by a glass pipette without disturbing the cell pellet. For 
the cell pellet prepared from the lymph nodes, resuspend the pellet in 5 ml medium, and count 
cells with hemocytometer under a upright microscope, (20x objective). Trypan-blue is used to 
exclude the dead cells. Adjust the density to 10 x 106 cells/ml 
6). For a single cell suspension prepared from spleen or thymus, resuspend the pellet in 3 
ml red blood cell lysis buffer per spleen/thymus. Incubate the cell suspension at room 
temperature for 5 minutes.  
7). Add an equal volume of medium, mix well, and centrifuge for 1,000 rpm x 5 minutes 
at 4 °C. Resuspend the cell pellet in 10 ml medium per spleen or thymus. Count cells and adjust 
the density to 10 x 106 cells/ml 
3.5 Generation of primary CD4 T cell responses to soluble peptide antigens by 
immunization 
Materials 
Mice with identified transgenic HLA genotype 
Synthesized peptides (>95 % purity), see Table 2 (Sigma-Genosys, Woodlands, TX) 
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Hank’s Balanced Salt Solution (Invitrogen, Carlsbad, CA) 
DMSO (Sigma, St. Louis, MO) 
Complete Freund’s Adjuvant (Difco, Detroit, MI) 
 
Table 2. Peptides used to prime HLA-DQ8 and HLA-DQ8/DR4 transgenic mice. 
 
Red blood cell lysis buffer 
Trypan-blue 
2 % NMS supplemented DMEM complete medium 
Hamilton gastight syringes, 1 ml (Fisher, Pittsburgh, PA) 
Double-hub Micro-Emulsifying needles, 18 G (Fisher, Pittsburgh, PA) 
B-D hypodermic needles, 25 G (Fisher, Pittsburgh, PA) 
Autoclaved scissors and forceps 
Autoclaved glass homogenizer  
250-ml filter unit, 0.22 um 
50-ml and 15-ml conical tubes 
Cell strainer, 40 um 
Hemocytometer 
Costar 24-well cell culture plate (Cardinal Health, McGaw Park, IL) 
Centrifuge 
Inverted and upright microscope 
37 ºC, 10 % CO2, Incubator 
 
1). Dissolve the peptides hGAD65101-115, hGAD65121-140, hGAD65536-550 in HBSS buffer 
to a final concentration of 2 mg/ml. Dissolve the peptide hGAD65206-220 in DMSO to a final 
concentration of 10 mg/ml for storage, and dilute this peptide with HBSS buffer to final 
concentration of 2 mg/ml prior to immunizing.  
 
Amino acid sequence
hGAD65101-115 CDGERPTLAFLQDVM
hGAD65121-140 YVVKSFDRSTKVIDFHYPNE
hGAD65206-220 TYEIAPVFVLLEYVT
hGAD65536-550 RMMEYGTTMVSYQPL
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2). Mix peptide solution with an equal volume of CFA (Normally, 100 ug of peptide is 
required for each mouse, and 4 mice will be assigned as a group to receive immunization with 
the same antigen). In order to improve emulsification, transfer the mixture into two gastight 
syringes connected by a double-hub micro-emulsifying needle and repeatedly force peptide/CFA 
mixture through the double-hub needle. 
3). Inject mice subcutaneously at the base of the tail, 100 ul emulsion per mouse.  
4). One week after immunization, sacrifice the mice and remove draining inguinal and 
periaortic lymph nodes and spleens. 
5). Prepare lymph node/spleen single cell suspension in 2 % NMS supplemented DMEM 
complete medium. 
6). Mix  an equal number of lymph node cells and spleen cells, transfer cell suspension 
into 24-well cell culture plates at 2 ml/well, with 10 ug/ml of cognate peptide. Incubate the plates 
in a humidified 37 °C 10 % CO2 incubator for 7 days. 
3.6 In vitro antigen-specific CD4 T cell culturing 
Materials 
Cells from previous in vitro culture 
Single cell suspension prepared from syngenic mouse spleen 
Peptide stocking solution 
Recombinant mouse interleukin-2 (rmIL-2) (Roche, Indianapolis, IN) 
10 % FBS supplemented DMEM complete medium 
T25 cell culture flask (Cardinal Health, McGaw Park, IL) 
Hemocytometer 
Centrifuge 
Shepherd Mark I 137Cs-sourced irradiator 
Incubator 
Inverted and upright microscopes 
 
1). Prepare single cell suspension from syngenic mouse spleen 
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2). With the cell suspension incubating on ice, irradiate the splenocytes with 2, 500 rads 
using a 137Cs-sourced irradiator. 
3). Centrifuge 1,000 rpm x 5 minutes at 4 °C. Aspirate the liquid, resuspend the cell 
pellet in 10 % FBS DMEM complete medium. Count cells, adjust the density to 10 x 106 
cells/ml. 
4). Establish a 20-ml restimulation culture in a T25 flask containing 25 x 106 irradiated 
splenocytes, 1 x 106 cells harvested from previous culture, 5-10 ug/ml of cognate peptide, 2.5-5 
unit/ml of recombinant mouse IL-2.  
5). Place the T25 flask in an upright position in a humidified 37 °C 10 % CO2 incubator.  
6). Repeat the restimulation protocol every two weeks. 
 
3.7 Characterizing in vitro T cell culture – examining CD4, CD8 and TCR Vβ  
expression 
Materials 
T cells from day-12~14 restimulation culture 
FACS staining buffer and fixation buffer 
FITC-conjugated anti-mouse TCR Vβ panel; PE-conjugated rat anti-mouse CD4 mAb, 
GK1.5; APC-conjugated rat anti-mouse CD8 mAb, 53.6.7; purified anti-mouse CD16/32 mAb, 
2.4G2 and antibody isotype controls (BD/Pharmingen, San Diego, CA) 
BD FACSCalibur Flow Cytometer 
 
1). Harvest the cells by centrifuging 
2). Wash the cell pellet once with FACS staining buffer 
3). Resuspend the cell pellet in 50 ul of anti-CD16/32 mAb solution for 15 minutes at 
room temperature 
4) Aliquot an equal volume of the cell suspension into different tubes, label the cell 
suspension with anti-CD4, -CD8 and TCR Vβ mAb panel.  
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5). Analyze staining results with flow cytometer to determine the expression of CD4, 
CD8 and TCR Vβ. 
3.8 MACS and FACS for T cell fractionation (optional protocol) 
Materials 
T cells from day-12~14 restimulation culture 
MACS anti-mouse CD8a (Ly-2) Microbeads (Miltenyi, Auburn, CA) 
MACS staining buffer 
1x PBS, pH7.2 
0.5 % BSA 
2 mM EDTA 
FACS staining buffer and fixation buffer 
FITC-conjugated anti-mouse TCR Vβ panel; PE-conjugated rat anti-mouse CD4 mAb, 
GK1.5; APC-conjugated rat anti-mouse CD8 mAb, 53.6.7; purified anti-mouse CD16/32 mAb, 
2.4G2 and antibody isotype  controls 
Centrifuge 
MACS LS and MS column (Miltenyi, Auburn, CA) 
MACS separator (Miltenyi, Auburn, CA) 
BD FACSCalibur Flow Cytometer 
BD FACSVantage DIVA Cell Sorter 
The purpose of this optional protocol is to obtain a relatively pure CD4 T cell subset 
from an in vitro T cell culture that contains CD4+ and CD8+ T cells, or CD4+ T cells expressing 
distinct TCR Vβs. Steps from 3) to 9) are used to pre-clear CD8+ T cell contamination (if it is 
applied). Cell sorting is eventually required to separate each individual subset to obtain a highly 
homogeneous cell population. It is not necessary if the T cell culture is composed of a 
homogeneous CD4 T cell population. 
1). Harvest the cells from day-12~14 restimulation culture by centrifuging. 
2) Wash the cell pellet with FACS staining buffer once and count cells. 
 45 
3). Resuspend the cell pellet in MACS staining buffer at a volume of 40 ul buffer/1x107 
cells, add the CD8a microbead suspension at a concentration of 10 ul microbeads/1x107 cells.  
4). Incubating at 4-8 ºC for 15 minutes 
5). Wash the cell suspension with MACS buffer (10-20 fold of labeling volume)  
6). Centrifuge and resuspend the cell pellet with 0.5 ml MACS staining buffer 
7). During the centrifugation, place a MACS LS or MS column in magnetic field of a 
MACS separator, and rinse the column (0.5 ml for MS column and 3 ml for LS column). 
8). Apply the cell suspension onto the column, wait till entire cell suspension passes 
through the column by gravity, then wash the column with a 3-fold rinsing volume of MACS 
staining buffer.  
9). Collect/combine total effluent, and centrifuge to remove the MACS buffer. 
10). Resuspend the cell pellet with FACS buffer and label the cells with anti-CD4, -CD3, 
or TCR Vβ antibody panel. 
11). Apply labeled cells onto a cell sorter to separate the subpopulations that differ from 
each other by their surface marker expression. 
12). Confirm the result of sorting by analyzing a small volume of sorted subpopulations 
on a regular flow cytometer. 
13). Once the purity is assured, use sorted cell populations for next round of restimulation 
culturing. 
 
3.9 In vitro CD4 T cell assay using irradiated mouse splenocytes as antigen presenting 
cells 
Materials 
T cells from day-12~14 restimulation culture 
Irradiated mouse splenocytes 
Peptides 
10 % FBS DMEM complete medium 
3H-TdR, 1mCi/ml stock solution, 6.7 Ci/mmol (Perkin Elmer, Wellesley, MA)  
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Ultima Gold Scintillation Fluid (Perkin Elmer, Wellesley, MA) 
Costar round-bottom 96-well cell culture plate (Cardinal Health, McGaw Park, IL) 
OmniFilter-96 microplate (Perkin Elmer, Wellesley, MA) 
Glass fiber filters (Perkin Elmer, Wellesley, MA) 
MiscoBeta FilterMate – 96-well cell harvester (Perkin Elmer, Wellesley, MA) 
Microplate Scintillation Counter (Packard, Meriden, CT) 
 
1). Prepare irradiated splenocyte suspension in 10 % FBS DMEM complete medium, and 
adjust the density to 10 x 106 cells/ml. 
2). Harvest T cells from the restimulation culture, wash once with complete medium, 
adjust the density to 2 x 105 cells/ml. 
3). Setup the peptide recall assay in a round-bottom 96-well plate. Each assay well 
contains 0.5 x 106 irradiated splenocytes, 20-50 x 103 T cells from the restimulation culture, and 
indicated amount of peptide. The assay is normally applied in triplication.  
4). Setup control wells either containing responder T cells only, and responder T cells 
together with splenocytes. 
5). To detect the cytokine production, harvest 150 ul of assay supernatant at 48 hours for 
IL-4 measurement, or 66 to 72 hours supernatant for IFN-γ measurement. 
6). ELISA is performed to determine the cytokine production. (See next section) 
7). To evaluate the cell proliferation, 66 to 72 hours co-culture is pulsed with 1 uCi 3H-
TdR (dilute 50-fold from 1 mCi/ml stock solution) for 6 hours followed by freezing down whole 
assay plate at -20 ºC. 
8). On the next day, thaw the assay plate, harvest contents of each assay well to a glass 
fiber filter using a 96-well cell harvester. 
9). Align the fiber filter onto an OmniFilter-96 microplate, add 25 ul of scintillation fluid 
to each assay well. 
9). Mount the microplate onto a Microplate Scintillation Counter to measure the 
incorporation of the 3H-TdR. 
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3.10 Enzyme-linked immunosorbent assay (ELISA) 
Materials 
T cell assay supernatant 
Coating buffer: 50mM NaHCO3, pH9.6 
Blocking buffer 
1 x PBS, pH7.4 
3 % BSA (w/v) 
0.02 % Na3N (w/v) 
25x DELFIA Washing concentrate; DELFA assay buffer; DELFIA enhancement 
solution; DELFIA Europium-Streptavidin; DELFIA 96-well yellow microtiter plate (Perkin 
Elmer, Wellesley, MA) 
ELISA capture antibodies: anti-mouse IFN-γ, R4-6A2; anti-mouse IL-4, BVD-1D11; 
anti-mouse IL-2, JES6-1A12 (BD/Pharmingen, San Diego, CA) 
ELISA detection antibodies: anti-mouse IFN-γ, XMG1.2; anti-mouse IL-4, BVD-24G2, 
anti-mouse IL-2, JES6-5H4 (BD/Pharmingen, San Diego, CA) 
ELISA recombinant cytokine standards: recombinant mouse IFN-γ, IL-4, IL-2 
(BD/Pharmingen, San Diego, CA) 
Microtiterplate Washer (Bio-Rad, Hercules, CA) 
VICTOR2 MicrotiterPlate Reader (Perkin Elmer, Wellesley, MA) 
DeltaSoft 3 (Bio-Rad, Hercules, CA) 
 
1). Coat a 96-well DELFIA yellow microititerplate with capture antibody (cap) dilutent, 
100 ul/well, 4 °C incubation over night.  
 10 ul 0.5 mg/ml anti-IL-2(cap) stock into 10 ml coating buffer, final conc. 0.5 ug/ml 
 30 ul 1.0 mg/ml anti-IFN-γ (cap) stock into 10 ml coating buffer, final conc. 3 ug/ml  
10 ul 0.5 mg/ml anti-IL4 (cap) stock per 10 ml coating buffer, final conc. 0.5 ug/ml 
2). Discard the antibody solution, add 300 ul of blocking buffer to each well and incubate 
at 37 °C for 2 hours 
3). Wash the plate with washing buffer 3 times. 
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4). Add 100 ul sample and recombinant protein standard into assigned wells, triplication 
or duplication is required, 4 °C incubation overnight. 
Standard starting solution: 
10 ul 2 ug/ml IL-2 into 2 ml blocking buffer, final conc. 10 ng/ml 
     25 ul 2 ug/ml IFN-γ into 2 ml blocking buffer, final conc. 25 ng/ml 
    2 ul 50 ug/ml IL-4 into 2 ml blocking buffer, final conc. 50 ng/ml 
   1: 2 series dilution is applied to dilute the standard. 
5).Discard the liquid,  wash the plate 4 times with washing buffer. 
6). Dilute secondary antibody (det) with blocking buffer, pipette 100 ul/well, incubate the 
plate at room temperature for 1 hour.  
 10 ul 0.5 mg/ml anti-IL-2(det) into 10 ml blocking buffer, final conc. 0.5 ug/ml 
 10 ul 0.5 mg/ml anti-IFN-γ (det) into 10 ml blocking buffer, final conc. 0.5 ug/ml 
10 ul 0.5 mg/ml anti-IL-4 (det) into 10 ml blocking buffer, final conc. 0.5 ug/ml 
7). Wash the plate with washing buffer and add 100 ul of 1: 1000 diluted Eu-conjugated 
Streptavidin (use DELFIA assay buffer to dilute), incubate the plate at room temperature for one 
hour with slow shaking and protect from light. 
8). Wash the plate and add 200 ul DELFIA enhancement solution to each well and shake 
the plate with a plate shaker for 5 minutes.  
9). Measure the fluorescence on the VICTOR2 MicrotiterPlate Reader under time-
resolved fluorometer module. 
10). Raw data is processed by DeltaSoft 3 for standard curve and cytokine concentration 
calculations. 
3.11 T hybridoma generation 
Material 
T cells from day-5 restimulation culture 
BW5147α-β- T lymphoma (courtesy of Dr. Willi Born, University of Colorado Health 
Science Center) 
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Mouse thymocyte suspension 
50 % PEG-1500 (v/v, in non-supplemented DMEM medium), pH neutral (Sigma, St. 
Louis, MO), autoclave sterilization 
Non-supplemented DMEM medium 
20 % FBS supplemented DMEM complete medium 
50x HAT supplement (Invitrogen, Carlsbad, CA) 
100x HT supplement (Invitrogen, Carlsbad, CA) 
Trypan blue 
Flat-bottom 96-well cell culture plate 
12-well cell culture plate 
Hemocytometer 
Inverted and upright microscopes 
Centrifuge 
37 °C water bath 
Incubator 
 
1). Euthanize 4-week old syngenic mice, prepare a single cell suspension of thymocytes 
at a density of 10 x 106 cells/ml in 20 % FBS supplemented DMEM complete medium. Place the 
thymocyte suspension in a 37 °C water bath. 
2).Harvest CD4 T cells from day-5 restimulation culture by centrifugation 1,000 rpm x 5 
minutes at room temperature. Wash the cells twice with 37 °C pre-warmed DMEM medium 
(without serum supplements) to remove residual amount of serum and antibiotics. 
3). Resuspend T cells in non-supplemented DMEM medium. Use trypan-blue to 
determine the viability. Normally, 95 % viability is required for a successive cell fusion reaction. 
Place the CD4 T cell suspension in the 37 °C water bath. 
4). Harvest exponential growth phase BW5147α-β- lymphomas by centrifuge, wash the 
cells twice with DMEM, determine the viability with the aid of trypan blue. 95 % viability is 
required. 
5). Mix the lymphomas and activated CD4 T cells at a ratio of 5:1 in a 50 ml conical 
polypropylene tube and add 20 ml of 37 °C pre-warmed DMEM. 
6). Centrifuge the cell mixture, 2,000 rpm x 5 minutes at room temperature. 
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7). Aspirate the liquid from the mixed-cell pellet  
8). Add 1 ml of 37 °C pre-warmed 50 % PEG solution in drop-wise manner to the mixed 
cell pellet, with gentle stirring of the pellet with the pipette tip following each drop.  
9). Drop-wise, add 2 ml of pre-warmed DMEM to the PEG/cell mixture over a period of 
2 minutes, gently stirring after each drop. Likewise, add an extra 7 ml of pre-warmed DMEM to 
the mixture over a period of 3 minutes. 
10). Centrifuge 2,000 rpm x 5 minutes at room temperature.  
11). Aspirate the liquid and use a 10-ml pipette to forcefully discharge 10 ml of 
thymocyte suspension onto the cell pellet. 
12). Add the rest of the thymocytes until the desired volume is reached (10 ml for each 
plate).  
13). Plate 100 ul cell suspension to each well of a flat-bottom 96-well plate (an estimating 
density of the T cells is around 100-500 cells/well). Place the plates in a humidified 37 °C 10 % 
CO2 incubator. 
14). After 1 day of incubation, add 100 ul of DMEM complete medium supplemented 
with 20 % FBS and 2x HAT supplement to each well of the culture plates. Return the plates to 
the incubator. 
15). On day 3 after fusion, monitor the cells under an inverted microscope. At this point, 
most non-hybrid cells should be dead while hybrids have not yet had a chance to grow out. 
16). On day 7 after fusion, aspirate 100 ul supernatant of each well and discard it. Feed 
the hybridomas by adding 100 ul of freshly prepared DMEM complete medium containing 20% 
FBS and 2 X HAT supplement. 
17). On day 10 after fusion, check the plates daily for the need to expand. Expand the 
content of the wells that have become slightly yellow by transferring the cells to the wells of a 
12-well cell culture plate. Add 3 ml of DMEM complete medium with 10 % FBS and 1x HT 
supplement to each well. 
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3.12 Screening for hybridomas with biological phenotype and function 
Materials 
T Hybridomas from the 24-well expansion plates 
Syngenic mouse splenocytes suspension, 2,500 rads irradiated 
Peptide 
Round-bottom 96-well tissue culture plates 
Fluorescence-conjugated anti-mouse CD3 mAb, anti-mouse CD4, anti-mouse TCR Vß 
panel 
Reagents for surface staining  
Reagents for IL-2 ELISA  
BD FACSCalibur Flow Cytometer 
Microtiter Plate Washer 
Microtiter Plate Reader 
Incubator 
 
1). Around 2-3 days after expansion, collect 2 ml of the cell suspension from wells that 
appear to be expanding for primary screening for the TCR/CD3 complex and CD4 expression 
using PE-conjugated anti-CD3 mAb, APC conjugated anti-CD4 mAb, and FITC-conjugated anti-
specific-TCR-Vβ mAb (if the usage of TCR Vβ by parental T cell line is known).  
2). Only a portion of the hybridomas identified in the primary screening as 
CD3+CD4+TCR+ will be qualified for the next round of screening.  
3). Secondary screening consists of Ag-specific in vitro T cell assay using selected 
hybridomas as responder cells. 
4). Candidate hybridomas were plated into round-bottom 96-well culture plates in 
duplicate at 50,000 cells/well, in the presence of 500,000 cells/well of irradiated syngenic 
splenocytes and 10 ug/ml of cognate peptide. Negative controls that contain only hybridomas 
and splenocytes but no peptide are also required for the assay. 
5). Incubate the 96-well plates for 24 hours in a humidified 37 °C 5 % CO2 incubator. 
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6). Harvest and combine 150 ul of supernatant from the wells with the same contents. 
Freeze the supernatant at -20 °C for >1 hour to kill any of the hybridoma cells that may have 
been transferred with the supernatant. 
7). Thaw the supernatant, and perform ELISA to determine the IL-2 production. 
8). Expand the hybridomas (that are capable to produce IL-2 upon cognate peptide 
restimulation) for freezing and re-cloning by limiting dilution. 
3.13 In vitro T hybridoma assay using mitogenically inactivated human B-LCL as 
antigen presenting cells 
Materials 
Human B Lymphoblast Cell Line (B-LCL): WT51, FS, KT17, BM92 
Exponential growth phase T Hybridoma 
Peptides  
Mitomycin C, 50 ug/ml, in non-supplemented DMEM 
10 % FBS supplemented RPMI complete medium 
RPMI 1640 medium (Gibco/Invitrogen, Palo Alto, CA) 
10 % Heat inactivated fetal bovine serum (FBS) (v/v) 
2 mM L-Glutamine 
5 mM HEPES buffer 
1 mM non-essential amino acid solution 
1 mM Sodium Pyruvate 
100 U/ml Penicillin, 100 ug/ml Streptomycin 
50 uM β-mercaptoethanol 
10 % FBS DMEM complete medium 
Round-bottom 96-well plates 
1). Human B-LCLs are normally maintained in RPMI 1640 complete medium 
supplemented with 10 % FBS and passaged once a week with 1:10-20 dilution. 
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2). Harvest human B-LCLs and inspect the viability with the aid of trypan-blue. 
Normally, 95 % viability is required. Dead cells can be removed by centrifugation over Ficoll-
Hyaque. 
3). Centrifuge 1,000 rpm x 5 minutes at room temperature. 
4). Aspirate the liquid and resuspend the pellet in 50 ug/ml Mitomycin C. Place the cell 
suspension in a 37 ºC water bath for 20 minutes 
5). Wash the B-LCLs twice with DMEM complete medium and resuspend the cells in 10 
% FBS DMEM complete medium at the density of 0.8 x 106 cells/ml 
6). Harvest T hybridomas. Likewise, 95 % viability is required. 
7). Setup the assay in a round-bottom 96-well tissue culture plate. Each well contains 40 
x 103 Mitomycin C inactivated B cells as antigen presenting cells, 20 x 103 T hybridomas as 
effector cells, and a variable amount of cognate peptide or un-relevant control peptide. 
8). Place the assay plate in a humidified 37  °C 5 % CO2 incubate for 24 hours 
10). Harvest the supernatant and perform ELISA to determine the IL-2 production. 
3.14 cDNA synthesis 
Materials 
Cells harvested from the cell culture  
TRIzol reagent (Invitrogen, Carlsbad, CA) 
Chloroform (Fisher, Pittsburgh, PA)  
Glycogen (Roche, Indianapolis, IN) 
Isopropanol (Sigma, St. Louis, MO) 
DEPC-treated water (RNase-free) (Ambion, Austin, TX) 
75 % Ethanol (v/v, in DEPC treated water) 
DNA-Free kit (Ambion, Austin, TX) 
SuperScript II First Strand cDNA Synthesis kit (Invitrogen, Carlsbad, CA) 
0.5-ml, 1.5-ml RNase-free microcentrifuge tubes (Ambion, Austin, TX) 
Spectrophotometer (LKB) 
Microcentrifuge (Kendro, Newtown, CT) 
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DNA Thermal Cycler (Perkin Elmer, Wellesley, MA) 
1). Harvest the cell culture by centrifugation. For adherent cells, it requires to dissociate 
the cells from tissue culture flask or dish with trypsin or cell dissociation buffer. Wash the cell 
pellet once with 1x PBS 
2). Centrifuge and remove the PBS. Resuspend the cell pellet in TRIzol reagent (1 ml 
TRIzol reagent is sufficient for 10x106 eukaryotic cells) and transfer contents to a 1.5 ml RNase-
free tube. Incubate the tube at room temperature for 2 minutes. 
3). Add 0.2 ml chloroform and incubate at room temperature for 3 minutes 
4). Centrifuge at 4 °C, 11,500 rpm x 15 minutes. Transfer aqueous phase to a new 1.5-ml 
RNase-free tube, add 1 ul of glycogen to facilitate precipitation, then add 0.5 ml isopropanol and 
incubate the sample on ice for 10 minutes. 
5). Centrifuge at 4 °C, 11,500 rpm x 15 minutes 
6). Descant the supernatant and use 75 % ethanol to wash the pellet once. Air-dry the 
pellet (<5 minutes at room temperature). Add 20 ul DEPC-treated water to dissolve the pellet. 
7). (Optional) Use DNase treatment to remove the DNA contamination. Briefly, transfer 
15 ul of the RNA sample from step 6) to a new 0.5 ml RNase-free tube containing 2 ul 10x 
DNA-free buffer and 1 ul of DNase (provided by DNA-free kit), add 2 ul of DEPC-treated water 
to make total volume up to 20 ul. Incubate the reaction tube at 37 ºC for 45 minutes. The reaction 
is then terminated by the addition of 2 ul DNase inactivation reagent provided by the same kit. 
Incubate the tube at room temperature for 2 minutes. Briefly centrifuge and transfer the aqueous 
fraction to a new 0.5 ml tube. The RNA sample is then ready for cDNA synthesis. 
8). Determine the yield of total RNA by examining the O.D260 absorbance using a 
spectrophotometer. 
9). Normally, 1-5 ug of total RNA is required as the template for cDNA synthesis using 
the reagents provided by the Superscript II First Strand cDNA Synthesis Kit. 
RNA sample                           5 ug 
10 mM dNTPs                        1 ul 
oligo dT                                 1 ul 
DEPC-treated H2O     up to 10 ul 
10). Incubate the sample in the DNA Thermal Cycler at 65 ºC for 5 minutes. Then place 
the sample on ice for 2 minutes, then add reagents listed below: 
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10 x RT buffer                        2 ul 
25 mM MgCl2                        4 ul 
0.1 mM DTT                          2 ul 
RNase inhibitor                     1 ul 
11). Incubate the sample at 42 ºC for 2 minutes, then add 1 ul of reverse transcriptase. 
Incubate the sample at 42 ºC for 50 minutes. 
12). Increase the temperature to 70 ºC for 15 minutes to inactivate the reverse 
transcriptase. 
13). Transfer the sample onto ice for 5 minutes, then add 1 ul of RNase H. Incubate the 
sample at 37 ºC for 20 minutes. 
14). cDNA synthesis is then accomplished. The sample is ready for PCR. 
3.15 Human HLA-DQA1*0301, DQB1*0302, DRA1*0101, DRB1*0401, and Ii (p33) 
cDNA cloning 
Materials 
cDNA prepared from WT51 (human B-LCL)  
BD Advantage cDNA PCR polymerase mix (BD/Clontech, Palo Alto, CA) 
Oligo-nucleotides for PCR primers (Table 3) (IDT, Inc., Coralville, IA) 
1Kb and 100 bp DNA ladder (Invitrogen, Carlsbad, CA) 
Agarose (Roche, Indianapolis, IN) 
50x TAE buffer 
242 g                        Trizma 
100 ml                     0.5 M EDTA, pH8.0 
57.1 ml                   Acetic Acid (glacial) 
1000 ml                  in total volume with addition of water 
Qiagen PCR cloning kit (Qiagen, Valencia, CA) 
Bacteria: DH5α competent cell (BD/Clontech, Palo Alto, CA) 
IPTG (Stratagene, La Jolla, CA) 
X-gal (Stratagene, La Jolla, CA) 
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Bacto Agar (BD, Palo Alto, CA) 
LB broth (Invitrogen, Carlsbad, CA) 
Ampicillin (Roche, Indianapolis, IN) 
QIAquick PCR purification kit (Qiagen, Valencia, CA) 
QIAprep MiniPrep plasmid DNA purification kit (Qiagen, Valencia, CA) 
Electrophoresis apparatus: power suppler/combs/trays/tank, etc. (Bio-Rad, Hercules, CA) 
GeneAmp PCR system 9600 (Perkin Elmer, Wellesley, MA) 
Spectrophotometer 
DNA Thermal Cycler 
3130 Genetic Analyzer (ABI, Fost City, CA) 
Sequencher v4.5 Software (Gene Codes Corporation, Ann Arbor, MI) 
1). WT51 (human B cell line) cDNA is prepared by SuperScript II First Strand cDNA 
Synthesis Kit. 
2) 50 ul PCR reaction is performed. A similar reaction without cDNA template is also 
setup as a negative control. 
0.5 ul              WT51 cDNA template 
5 ul                 10 x Advantage cDNA polymerase buffer (BD/Clontech, Palo Alto, CA) 
1 ul                 dNTPs mixture, 10 mM for each (Roche, Indianapolis, IN) 
1 ul                 Advantage cDNA polymerase (BD/Clontech, Palo Alto, CA) 
0.5 ul              Forward strand primer (20 uM)( Table I) 
0.5 ul            Reverse strand primer (20 uM) (Table I) 
41.5 ul          ddH2O 
50 ul 
3). PCR program setup 
1 cycle of 95 ºC incubation for 2 minutes 
30 cycles of 15 seconds incubation at 95 ºC, followed by 15 seconds incubation 
at annealing temperature (Table 3), and 60 seconds incubation at 68 ºC. 
1 cycle of 10 minutes incubation at 72  ºC 
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Table 3. PCR primers for cDNA cloning 
 
 
4). Apply electrophoresis to inspect and separate PCR products.  
5). Excise a single band PCR product from the agarose gel and extract the double-strand 
DNA from the gel by using QIAquick PCR purification kit. 
6). Measure the DNA concentration of purified PCR product. 
7). The ligation reaction is performed using a QIAgen PCR cloning kit. Briefly, 10 ul of 
ligation reaction composed by 5 ul of 2 x Master ligation mixture provided by the kit, and the 
mixture of PCR product and pDriver vector. Adjust the ratio of the molecule of PCR product to 
vector as 5:1. 
8). Perform the ligation reaction at 16 º for 30 minutes. 
9). Transform DH5α competent cells with ligation product and spread the bacterial 
suspension evenly on an LB agar plate contain 60 ug/ml Ampicillin and IPTG/X-gal. 
10). On the next day, pick 10 white colonies from each plate and inoculate into 3 ml 
ampicillin-supplemented LB medium. Grow the bacterial overnight. 
11). Harvest 1.5 ml bacteria culture and purify the plasmid DNA using QIAamp 
MiniPrep plasmid DNA purification kit. 
12). Apply DNA sequencing and analyze the results with the aid of Sequencher v4.5 
software to identify correct clones. 
 
Gene Forward primer Reverse primer
Annealing 
temp (ºC) PCR product
DQA1*0301 ACT GCT GAG GCT GCC TTG CCG CTG CTG TAG ATG GTG 61 821bps
DQB1*0302 CCA AGC TGT GTT GAC TAC C GGC GTT ACA GAA AAG TGA 54 861bps
DRA1*0101 AAC AGA GCG CCC AAG AAG A CCA TCA CCT CCA TGT GCC T 64 786bps
DRB1*0401 CTG GTC CTG TCC TGT TCT C GGT CAT CTT CAC TTC AGC TC 57 818bps
Ii (p33) CTC TTC CTT GGG GAG TGA TG GAT GTT GAA GAC CGC CTC TG 61 723bps
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3.16 Cloning strategies to generate bicistronic constructs for HLA-DQ8 and HLA-DR4 
cDNA expression in COS7 cell line 
Material 
pDriver-DQA1*0301, pDriver-DQB1*0302, pDriver-DRA1*0101, pDriver-DRB1*0401 
pDriver-eIF4-IRES (courtesy of Dr. William Rudert, University of Pittsburgh) 
pcDNA3.1/Zeo (+), pcDNA3.1 (Invitrogen, Carlsbad, CA) 
Restriction enzymes and reaction buffers: BamH I, EcoR I, EcoR V, Kpn I, Hind III, Pst 
I, Sal I, Xho I (Roche, Indianapolis, IN) 
Other enzymes: Klenow fragment (Roche, Indianapolis, IN), DNA ligase (Qiagen, 
Valencia, CA) 
dNTP mixtures, 10 mM for each (Roche, Indianapolis, IN) 
DH5α competent cells 
Low salt LB broth 
10 g                        Bacto-tryptone (Difco, Detroit, MI) 
 5 g                         Bacto-yeast extract (Difco, Detroit, MI) 
 5 g                         NaCl (Sigma, St. Louis, MO) 
Adjust volume to 1000 ml with deionized distilled H2O, autoclave sterilization 
Zeocin (Invitrogen, Carlsbad, CA) 
 
1). For constructing DQ8 expression vector (Figure 13), DQB1*0302 cDNA (encoding 
HLA-DQ8 β-chain) and IRES were cloned into pcDNA3.1/Zeo(+) vector between Kpn I and Pst 
I sites through a three-fragment ligation reaction. DQA1*0301 cDNA (encoding HLA-DQ8 α-
chain) was then cloned into intermediated vector between the EcoR V (located at immediate 
downstream of IRES) and Xho I sites. The “sticky” ends generated by Xho I and Sal I 
(underlined) digestion are mutually complement and can anneal to each other. The “blunting” in 
the bracket indicates a klenow fragment-mediated blunting reaction is applied after primary 
digestion reaction. 
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Figure 13. A bicistronic construct for HLA-DQ8 cDNA expression 
 
2). For constructing the HLA-DR4 expression vector (Figure 14), DRA1*0101 cDNA 
(encoding HLA-DR4 α-chain) was cloned into the pDriver-eIF4-IRES vector between EcoR V 
and Kpn I sites. DRB1*0401 cDNA (encoding HLA-DR4 β-chain) and the IRES-DRA1*0101 
fragment were subsequently cloned into pcDNA3.1 (+) expression vector between Nhe I and 
Kpn I sites through a three-fragment ligation reaction. The “blunting” in the bracket indicates a 
klenow fragment-mediated blunting reaction is applied after primary digestion reaction. 
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Figure 14. A bicistronic construct for HLA-DR4 cDNA expression 
 
3). The DQ8 expression vector was transformed into DH5α competent cells and selected 
on the low salt LB agar plate containing 25 ug/ml Zeocin. The DR4 expression vector was 
transformed into DH5α competent cells and selected on regular LB agar plate containing 60 
ug/ml Ampicillin. 
4). Plasmids purified from selected clones were examined by performing PCR and DNA 
sequencing to ensure the sequence of essential elements. 
 
 61 
3.17 Introduce HLA-DQ8 cDNA into COS7 cells by stable transfection 
Materials 
COS7 cell line (ATCC, Manassas, VA) 
pDQ8-Zeo (the bicistronic construct for HLA-DQ8 cDNA expression) 
Restriction enzyme and reaction buffer: Pvu I (New England BioLabs, Ipswich, MA) 
Agarose 
QIAquick PCR purification kit  
1x PBS, pH7.4 
Superfect transfection reagent (Qiagen, Valencia, CA) 
DMEM medium, without supplement 
10 % FBS supplemented DMEM complete medium 
6-well tissue culture dish (Cardinal Health, McGaw Park, IL) 
Electrophoresis apparatus  
 
1).  One day before the transfection, seed the COS7 cells at 20% confluence in a 6-well 
cell culture dish to ensure a 40-60% confluence will be reached on the day of transfection. 
2). On the same day, apply Pvu I restriction enzyme digestion to linealize the pDQ8-Zeo 
expression vector. 
pDQ8-Zeo                     20 ug 
Buffer H, 10 x               20 ul 
Pvu I                             10 ul 
ddH2O               up to 200 ul in total volume, 37 ºC incubation for 2 hours 
3). Apply 1% agarose gel electrophoresis and extract the 7.5 Kb band from agarose gel 
with the aid of QIAquick PCR purification kit. 
4). On the day of transfection, mix 2 ug of linealized pDQ8-Zeo DNA with 100 ul of 
DMEM medium. Add 10 ul of Superfect transfection reagent into the DNA mixture, gently 
pipetting the mixture two times. Incubate the tube at room temperature for 10 minutes and avoid 
of further disturbing.  
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5). During the incubation (the process in which DNA binds transfection reagent 
particles), aspirate the culture medium from the COS7 cells and wash the COS7 cells with 1 x 
PBS twice without dislodging the monolayer. 
6). Add 400 ul 10% FBS supplemented DMEM complete medium to the DNA/Superfect 
mixture, gently pipetting twice to mix the content evenly, then drop-wise transfer the transfection 
mixture onto the COS7 monolayer. Place the cells at the 37 ºC 5% CO2 incubator for 5 hours. 
7). Remove the transfection mixture from the COS7 cells and wash the monolayer twice 
with 1x PBS. Add 3 ml 10 % FBS supplemented DMEM complete medium and place the cells in 
the 37 ºC incubator for 24 hours prior to selecting stable transfected clones. 
3.18 Select and identify pDQ8-Zeo stable-transfected COS7 cells 
Materials 
Transfected COS7 cells 
TH536.1 T Hybridoma 
hGAD65536-550 peptide 
Zeocin 
Trypsin-EDTA (Invitrogen, Carlsbad, CA) 
10 % FBS-supplemented DMEM complete medium 
TRIzol reagent 
Reagents for RT-PCR 
FACS staining buffer and fixation buffer 
FITC-conjugated anti-HLA-DQ mAb and isotype control 
IL-2 ELISA reagents 
Cloning disc, 3 mm (ID) (Fisher, Pittsburgh, PA) 
Autoclaved fine-tip forceps 
10 cm cell culture dish (Cardinal Health, McGaw Paw Park, IL) 
Flat-bottom 96-well cell culture dish (Cardinal Health, McGaw Paw Park, IL) 
12-well cell culture dish 
T25 cell culture flask 
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Inverted microscope 
1). After 24 hours of transfection, dissociate the monolayer with trypsin-EDTA. 
Centrifuge to remove the culture medium. Resupend the cell pellet in 11 ml of DMEM complete 
medium. 
2). Apply a series of 10-fold dilutions starting from 100 to 10-1, 10-2, 10-3 and 10-4 in 
individual 10 cm cell culture dishes containing 10 ml DMEM complete medium, supplemented 
with 400 ug/ml of Zeocin. Place the dishes in the 37 ºC 5 % CO2 incubator. 
3). Monitor the monolayer everyday and replace the selection medium every 4 days. 
After one week, in highly diluted dishes, some new-formed colonies will be observed.  
4). Mark the position of the colonies at the bottom of the dishes with the aid of an 
inverted microscope. Transfer the marked colonies to the wells of a flat-bottom 96-well plate 
with a trypsinized cloning disc. 
8). On the next day, remove the cloning disc from each individual well. Maintain the cell 
clones in 96-well plates under Zeocin selection and monitor the growth of the colonies every two 
days after one week. Dissociate the cells from the wells reaching 60 % confluence and transfer 
the cells to a 12-well cell culture dish for expansion. Further expansion to a T25 flask is required 
when the cells growing in the 12-well dishes reach full confluence. 
9). Identify the selected colonies for the expression of transfected cDNA by RT-PCR the 
assembly of DQ8 α-/β-chain by FACS surface staining, and the function of DQ8 by T 
hybridoma assay (Functional DQ8 should be able to present peptide and induce antigen-specific 
T cell responses). 
3.19 Cloning strategies for generating a CLIP-substituted recombinant invariant chain 
that carries hGAD65539-547 coding sequence 
Materials 
pDriver-hIi  
Restriction enzyme and reaction buffer: Hind III, EcoN I, PinA I, Nde I, Kpn I, Not I 
            (New England Biolabs, Ipswich, MA) (Roche, Indianapolis, IN) 
Other enzymes: DNA ligase (Qiagen, Valencia, CA) 
 64 
Oligo-nucleotides: (IDT, Inc., Coralville, IA) 
5ARM-adaptor (+): 5’-AGC TTC CCA AAG CCT CCC AAA CCG GTG-3’ 
5ARM-adaptor (-): 5’- AAT TCA CCG GTT TGGGAG GCT TCC CA-3’ 
3ARM-adaptor (+): 5’ AAT TCT GCC CCA TAT GGG AGC CCT GC-3’ 
3ARM-adaptor (-):  5’-GGC AGG GCT CCC ATA TGG GGC AG-3’ 
DH5α competent cells 
pcDNA3.1 (+) 
 
 
 
Figure 15. The generation of CLIP-substituted recombinant invariant chain (rIi) “cassette” 
 
1). Original CLIP coding sequence was removed from Ii (p33) between Hind III and 
EcoN I sites (Figure 15), and replaced by a “cassette” created from two double-strand oligo-
nucleotides (5’ARM adaptor and 3’ARM adaptor) that partially overlapped with Ii cDNA 
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through a three-fragment ligation reaction. The 5’ARM adaptor and 3’ARM adaptor introduced a 
GA mutation, a TA mutation and a CT mutation so that a PinA I and an Nde I site were 
generated in the place where the original CLIP was but not affecting the Ii coding sequences 
flanking the CLIP region. In order to generate a CLIP –substituted rIi, the PinA I-Nde I fragment 
– a DNA “cassette” was then replaced by a double-stranded oligo-nucleotide a carrying peptide 
coding sequence such as p539 (hGAD65539-547) and “sticky” ends complemented to the single 
strand DNA extruded-ends generated by PinA I and Nde I.  
2). The CLIP-substituted hrIi-539 that encodes the hGAD65539-547 sequence was cloned 
into the pcDNA3.1 (+) expression vector between Kpn I and Not I sites. DNA sequencing was 
applied to confirm the sequence of the recombinant invariant chain. 
3.20 Transient transfect CLIP-substituted hrIi-539 into DQ8+ COS7 cells and T 
hybridoma responses 
Materials 
DQ8+ COS7 cell (DQ8#114) 
TH536.1 
hrIi-539 (CLIP was replaced by hGAD65539-547 coding sequence) 
Superfect transfection reagents 
DMEM medium (without supplements) 
10 % FBS supplemented DMEM complete medium 
Trypsin-EDTA 
1x PBS 
Trypan-blue 
6-well cell culture dish 
Flat-bottom 96-well cell culture plate 
Inverted and upright microscope 
 
1). One day before the transfection, seed the DQ8+ COS7 into a 6-well cell culture dish at 
40 % confluence to ensure 60-80 % of confluence on the day of transfection 
 66 
2). Apply transfection with 2 ug of circular hrIi-539 plasmid DNA together with 10 ul of 
Superfect transfection reagent. 
3). Dissociate the transfected monolayer 24 hours later and re-seed the cell to a flat-
bottom 96-well plate at the density of 5,000 cells/well in triplicate 
4). Place the plate in a 37 ºC incubator overnight, then add TH536.1 hybridomas.  
5). Harvest the supernatant 24 hours later for ELISA to determine the IL-2 production. 
3.21 Statistics 
The results were analyzed using Prism 4 software (GraphPad Software, Inc., san Diego, 
CA). The difference of T cell responses elicited by DQ8 vs. DQ8/DR4 transgenic splenocytes 
were assessed by one-tailed unpaired t test. The results of T hybridoma responses against a panel 
of B-LCLs were analyzed by one-way ANOVA. A p-value < 0.05 was considered statistically 
significant. 
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4.0  RESULTS/FINDINGS 
4.1 Generation of antigen-specific CD4 T cell lines and hybridomas 
4.1.1 Breeding and genotyping mice with human HLA-DQ8 and/or -DR4 transgenes 
An important step of this study was to obtain an antigen presenting system that segregated DQ8 
from DR4. This was impossible to achieve by using human samples since human APCs 
expressed DQ and DR simultaneously. Thus, two previously (and also independently) generated 
HLA transgenic mouse strains were used instead (10, 153). As the DQ8 and DR4 transgene were 
not located on the same chromosomes, they would be transmitted independently to the offspring 
generation during the interbreeding process. Therefore, by crossing DQ8 transgenic mice with 
DR4 transgenic mice, we expected to obtain mice expressing:  
  
1) DQ8 and DR4 together  
2) DQ8 alone 
3) DR4 alone 
4) Neither DQ8 nor DR4 
 
Mice were genotyped for HLA expression at 3-4 weeks of age, by determining the HLA 
expression on the surface of B cells.  Briefly, peripheral blood was collected and stained by 
fluorescence-conjugated monoclonal antibodies specific for the HLA-DQ, HLA-DR and B cell 
surface marker CD45R (B220). Staining results of DQ8+DR4+ (Figure 16C), DQ8+DR4- 
(Figure 16D), DQ8-DR4+ (Figure 16E), and DQ8-DR4- mouse (Figure 16F) were revealed by 
flow cytometry analysis, respectively. The fluorescence intensity was utilized to quantitate the 
relative expression level of DQ8 or DR4, which was required for subsequent experiments in this 
study. 
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4.1.2 Generation and characterization of antigen-specific primary CD4 T cell lines 
Four candidate peptides -- GAD65101-115, hGAD65121-140, hGAD206-220, and hGAD65536-550 were 
chose to generate CD4 T cell lines, which expressed TCRs only recognizing cognate peptides in 
the context of DQ8 binding site. These peptides were derived from human GAD65 — a putative 
autoantigen of human T1D. They were previously demonstrated to be able to bind HLA-DQ8 
molecules (154). Four groups of HLA-DQ8 transgenic mice were immunized by an individual 
peptide. After a week, an in vitro primary T cell culture was established followed by biweekly 
cognate peptide restimulation (Figure 17A)(155). Within the first few days after restimulation, 
antigen-specific T cells were activated and manifested an enlarged morphology (Figure 17B) 
that could be easily monitored by microscopic observation. In contrast, the size of non-activated 
T cells was relatively small and undistinguishable from other splenocytes (Figure 17C). 
Repeated restimulation was actually a selection process. Since only those antigen-specific T cells 
received activation signals through their TCRs that engaged the peptide:DQ8 complex on the 
surface of APCs, they survived and expanded in culture. In contrast, non-specific T cells were 
eliminated for the lack of the activation signal and negligible after six rounds of restimulation. In 
this way, four primary DQ8-restricted CD4 T cell lines were obtained, named DQ8p101, 
DQ8p121, DQ8p206, and DQ8p536, respectively. Results from in vitro proliferation assays 
showed that DQ8p101 (Figure 18A), DQ8p121 (Figure 18B), DQ8p206 (Figure 18C), and 
DQ8p536 (Figure 18D) specifically responded to their cognate peptides. 
4.1.3 T206, T536.1 and T536.2 – CD4 T cell lines with clonal phenotypes 
Although all four DQ8-restricted T cell lines specifically responded to their cognate peptides, the 
background of DQ8p101 and DQ8p121 responses were relatively higher than that of DQ8p206 
and DQ8p536 (Figure 18A, B, C and D). It implied poor quality of the cell line, probably due to 
a small fraction of non-specific T cell contamination that was kept alive by the IL-2 secreted 
from specific T cells. The DQ8p206 and DQ8p536 lines, manifesting low background responses 
upon antigen restimulation, were further characterized for the TCR β-chain expression. This was 
accomplished by flow cytometric analysis with a panel of fluorescence-conjugated anti-TCR Vβ 
monoclonal antibodies including Vβ2, 3, 4, 5.1/5.2, 6, 7, 8.1/8.2, 8.3, 9, 10, 11, 12, 13 14 and 17.  
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Staining results showed that the DQ8p206 cell expressed a single TCR Vβ6 (Figure 
19A). It was likely that the DQ8p206 line was derived from a single naïve CD4 T cell precursor  
(Each T cell only expresses one functional TCR β-chain). To further confirm this observation, 
the cDNA was prepared and RT-PCR (with Vβ6-specific primer paired with a common Cβ 
primer) was used to clone the DQ8p206 TCR β-chain VDJC joint fragment into a cloning vector 
for sequencing analysis. Sequence results showed all colonies were identical (Figure 19B). 
Therefore, DQ8p206 represented a clonal phenotype and was renamed as T206. Cytokines 
produced by T206 upon antigen recall were also evaluated by IFN-γ and IL-4 ELISA. Results 
indicated T206 predominantly secreted IFN-γ, but no IL-4 (Figure 19C). It suggested that T206 
was a Th1-like CD4 T cell line.  
 
Staining result of DQ8p536 cell line showed that 50 % of CD4 T cells were Vβ11+ 
(Figure 20A), whereas the remaining population could not be unambiguously verified by 14 
other different Vβ antibodies. It suggested that this cell line was composed of T cells derived 
from different precursors and Vβ11- subset could express some rare β-chains that were not 
covered by the commercially available Vβ antibody panel. Hence, the Vβ11- subset was 
separated from the Vβ11+ subset by cell sorting. RT-PCR was then applied with a panel of Vβ-
specific primers (Table 4) covering 24 different Vβ segments to identify the TCR β-chain of the 
Vβ11- DQ8p536 subset (156). Confirmed by sequencing analysis, this subset dominantly 
expressed Vβ1 (Figure 20B). The Vβ11- subset was then named T536.1. ELISA results 
indicated that T536.1 secreted both the Th1 cytokine IFN-γ and the Th2 cytokine IL-4 (Figure 
20C).  
 
The Vβ11+ DQ8p536 subset (Figure 21A) was also confirmed for the clonal phenotype 
by sequencing the TCR β-chain (Figure 21B), and was named T536.2. T536.2 secreted a Th2 
profile cytokine – IL-4, but not IFN-γ (Figure 21C). 
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Table 4. Oligo-nucleotides used as RT-PCR primers to screen TCR Vβ  usage (156) 
4.1.4 Cell fusion – to obtain T hybridomas 
A second class of T cell reagents prepared in this study was T hybridoma (157). They were 
generated by fusing activated primary T cells with a T lymphoma that didn’t express functional 
CD3/TCR complex. Unlike its parental T cell lines, T hybridoma can be maintained in culture 
medium without the requirement of antigen presenting cells and peptide restimulation. 
Meanwhile, it is also capable of responding to cognate antigen recall and secreting IL-2 (or IL-4, 
Mouse TCR V-segment-specific oligo-nucleaotides
V -segment Sequence in forward direction
V!1 CT GAA TGC CCA GAC AGC TCC AAG C
V!2 TC ACT GAT ACG GAG CTG AGG C
V!3.1 CCT TGC AGC CTA GAA ATT CAG T
V!4 GCC TCA AGT CGC TTC CAA CCT C
V!5.1 CAT TAT GAT AAA ATG GAG AGA GAT
V!5.2 AAG GTG GAG AGA GAC AAA GGA TTC
V!5.3 AG AAA GGA AAC CTG CCT GGT T
V!6 CT CTC ACT GTG ACA TCT GCC C
V!7 TAC AGG GTC TCA CGG AAG AAG C
V!8.1 CAT TAC TCA TAT GTC GCT GAC
V!8.2 CAT TAT TCA TAT GGT GCT GGC
V!8.3 T GCT GGC AAC CTT CGA ATA GGA
V!9 TCT CTC TAC ATT GGC TCT GCA GGC
V!10 ATC AAG TCT GTA GAG CCG GAG GA
V!11 G CAC TCA ACT CTG AAG ATC CAG AGC
V!12 C ATG GTG GGG CTT TCA AGG ATC
V!13 AGG CCT AAA GGA ACT AAC TCC CAC
V!14 AC GAC CAA TTC ATC CTA AGC AC
V!15 CCC ATC AGT CAT CCC AAC TTA TCC
V!16 C ACT CTG AAA ATC CAA CCC AC
V!17 AG TGT TCC TCG AAC TCA CAG 
V!18 C AGC CGG CCA AAC CTA ACA TTC TC
V!19 CT GCT AAG AAA CCA TGT ACC A
V!20 TC TGC AGC CTG GGA ATC AGA A
Mouse TCR C-segment-specific oligo-nucleotide
CTT GGG TGG AGT CAC ATT TCT C
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depending on the nature of fusion partners). In addition, for unknown reasons, IL-2 secretion of 
T hybridoma upon antigen recall is less depended on the co-stimulation than primary T cell 
(158). It thus provides the convenience and the advantage for studying antigen presentation in 
the absence of co-stimulation. 
 
In this study, BW5147α-β-, a mouse T lymphoma devoid of the endogenous CD3 
complex and TCR α/β-chain was used as a fusion partner. Since this lymphoma does not express 
endogenous TCR, it guaranteed that the antigen specificity was limited to the TCR from primary 
T cell (159). Fused cells were selected with hypoxanthine/aminopterin/thymidine (HAT) 
supplemented medium followed by a two-step screening procedure. The first step was to screen 
for the TCR/CD3 expression by flow cytometry analysis. As BW5147α-β- doesn’t express a 
functional TCR/CD3 complex, only those hybridomas expressing CD3 and TCR identical to the 
parental T cell line would be selected for subsequent studies. Accordingly, TCR/CD3+ T 
hybridomas were screened for the ability of antigen-specific responses, and this procedure 
required both APCs and the cognate peptide (and a non-related peptide as control). A panel of 
CD4+Vβ6+ TH206 hybridomas was generated from T206 (Figure 22A). They all responded to 
cognate peptide hGAD65206-220 recall (Figure 22B). TH206#2 was empirically chosen for 
subsequent study since this clone manifested a highly uniform morphology under the 
microscope. TH536.1 hybridomas were obtained from T536.1, and they were selected by antigen 
recall assay (Figure 23) and RT-PCR for Vβ1 expression. TH536.2 hybridomas were obtained 
from T536.2. They were screened by Vβ11 expression (Figure 24A) and antigen-specific 
response (Figure 24B). TH536.1#36 and TH536.2#62 were chose for subsequent experiments. 
4.2 Evidence that DR4 (DRA1*0101/DRB1*0401) competes for peptides with DQ8 
(DQA1*0301/DQB1*0302) 
4.2.1 DQ8 and DR4 can bind same peptide 
In addition to the panel of DQ8-restricted CD4 T cell lines, another CD4 T cell line was 
generated from hGAD65206-220 immunized DQ8+DR4+ transgenic mice. Unlike other DQ8-
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restricted T cell lines, this cell line, named DR4p206, was maintained/selected by restimulation 
using DR4+ spleen cells as APCs. Results from in vitro restimulation assay showed that 
DR4p206 responded to the cognate peptide – hGAD65206-220 presented by both DR4+ and 
DQ8+DR4+ spleen cells but not DQ8+ spleen cells (Figure 25). It indicated that hGAD65206-220 
was associated with the DR4 peptide binding site to form the ligand that induced DR4p206 
response. It was noteworthy that hGAD65206-220 was the cognate peptide of the DQ8-restricted 
T206 cell (Figure 19C).  Therefore, it was clear that the same hGAD65206-220 peptide was able to 
bind both DQ8 and DR4 molecule. 
 
4.2.2 Co-expression of DR4 with DQ8 diminished DQ8-restricted T cell responses 
As DQ8 and DR4 were demonstrated to bind the same peptide, they potentially would compete 
for the source of peptide when DQ8 and DR4 were co-expressed on the same APC. In order to 
test this hypothesis, we then evaluated the relative peptide occupancy of DQ8 by comparing the 
CD4 T cell responses elicited by DQ8+ APCs (in the absence of DR4 expression) with 
DQ8+DR4+ APCs (in the presence of DR4 co-expression), using DQ8-restricted T206, T536.1 
and T536.2 as responding T cells. Since these T cell lines manifested homogeneous 
compositions, they were reliable to serve as detection reagents. Splenocytes from selected DQ8 
single transgenic and DQ8/DR4 double transgenic mice were used as APCs. FACS analysis was 
performed to ensure splenocytes from selected HLA transgenic mice expressing similar levels of 
HLA-DQ8 (Figure 26A). Both DQ8+ and DQ8+DR4+ splenocytes induced the T206 response for 
IFN-γ secretion, whereas in the presence of DR4, IFN-γ secretion was decreased (Figure 26B). 
A similar reduction in cytokine secretion was also observed using the T536.1 line as the 
responding T cell (Figure 26C). However, when T536.2 cells were used as responders, the result 
of in vitro restimulation assay showed that there was a slight difference in IL-4 release between 
the responses elicited by DQ8 APCs and DQ8/DR4 APCs (Figure 26D). This could be due to a 
relatively low proliferation rate shared by most Th2-like T cells such as T536.2. It responded to 
its cognate peptide by producing IL-4, but manifested limited expansion without the addition of 
exogenous IL-2 administration (Figure 27A). In contrast, T536.1 – the Th1 cell line expanded 
rapidly upon restimulation (Figure 27A), particularly in the absence of DR4 expression (Figure 
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27B). Rapid expansion certainly synergized the cytokine production since increasing numbers of 
T cells were involved in the assay. In summary, these results indicated that DR4 co-expression 
affected DQ8-restricted Th1 cell responses and led to diminished clonal expansion and IFN-γ 
production, whereas the response of the Th2 cell line T536.2 was less affected. Since the DQ8 
and DQ8/DR4 transgenic mice used in this comparison were from the same litter, the genetic 
differences (except DR4 expression) between these two transgenic groups were minimized, and 
should not account for the observed differences. 
4.2.3 A peptide blocking DR4 peptide binding site was able to partially recover DQ8-
restrcited T cell responses. 
The peptide competition requires a free DR4 peptide binding site. Diminished T cell responses 
observed in previous experiments thus suggested that a significant amount of peptide was able to 
access the DR4 binding site. In order to confirm this interpretation, we investigated hGAD65206-
220 and hGAD65536-550 presentation efficiency in the presence of blocking peptide – hGAD65554-
566, which was demonstrated previously to bind DR4 with a high affinity, but was not able to 
bind DQ8 at all (150). A human B cell line WT51 (expressing both DQ8 and DR4) was used as 
the APC and T hybridomas TH206 (Figure 28A), TH536.1 (Figure 28B), and TH536.2 (Figure 
28C) were used as detection reagents. Results showed that with increasing amounts of blocking 
peptide, T hybridoma responses were increased accordingly. It indicated that the peptide 
occupancy of DQ8 was at least partially recovered due to the saturation of the DR4 binding site 
with the blocking peptide. 
4.3 Different DR4 subtypes (DRB1*0401, 0402, 0403, 0404, and 0406) manifested 
different levels of modulation of DQ8-restricted CD4 T cell responses 
We next examined effects of other DR4 subtypes (DRB1*0401, 0402, 0403, 0404, and 0406) on 
DQ8-restricted CD4 T cell responses. It is noteworthy that DQ8-DRB1*04 haplotypes carrying 
distinct DRB1*04 alleles are associated with variable susceptibility to T1D (8, 146). These 
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DRB1*04 alleles differ from each other only by a few amino acid residues within peptide 
binding groove regions (Figure 29)(100). We thus suspected that the polymorphisms within the 
peptide binding groove would confer variable peptide competition potentials for these DR4 
subtypes. 
 
As transgenic mice expressing DR4 alleles other than DRB1*0401 have not been 
developed, the most available sources of antigen presenting cells are Epstein-Barr virus 
transformed human B cells – WT51, FS, BM92 and KT17 (International Histocompatibility 
Working Group (http://www.ihwg.org).  These four B cell lines express distinct DQ8-DRB1*04 
haplotypes (Table 5). It should be noted that they are homozygous at DQ-DRB1 loci except that 
KT17 heterozygously expresses DRB1*0403 and 0406 at DRB1 locus. However, since the 
amino acid sequence within the DR peptide binding groove is identical between 0403 and 0406, 
it is presumed that HLA-DR4 (0403) and HLA-DR4 (0406) manifest an identical affinity for 
peptide binding. 
 
Table 5. DQ-DRB1 haplotypes of selected B-LCLs 
 
Primary T cells (T206, T536.1 and T536.2) were not ideal to evaluate antigen presenting 
efficiencies of human B cells, because human B cells could not provide proper co-stimulation 
that had been demonstrated to be needed for primary T cell activation (158).  Hence, the T 
hybridomas – TH206, TH536.1 and TH536.2 were used for this purpose.  
 
We also noticed that TH206 was similar to its un-fused parental T cell line T206 and 
responded better to truncated hGAD65209-217 9-mer than cognate hGAD65206-220 15-mer (Figure 
WT51 FS KT17 BM92
DQA1 0301 0301 0301 0301
DQB1 0302 0302 0302 0302
DRB1 0401 0402 0403/0406 0404
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30). We thus decided to use truncated 9-mer hGAD65209-217 as antigen for subsequent T 
hybridoma response to obtain optimal sensitivity. 
 
Given a sufficient quantity of peptide, all of these human B cell lines were able to raise 
TH206, TH536.1 and TH536.2 responses (Figure 31A, B, C). However, the magnitude of T cell 
responses elicited by human B-LCLs was variable and ranked from high to low in the order of 
FS ≥ WT51 >BM92 >KT17. These variable T hybridoma responses were not correlated with the 
level of HLA-DQ8 expression (Figure 32). The lower DQ expressing B cell line FS 
(homozygous for DQ8-DRB1*402) always caused strong T cell responses. In contrast, those 
higher DQ-expressing cells such as BM92 (homozygous for DQ8-DRB1*0404), and KT17 
(homozygous for DQ8, heterozygous for DRB1*0403/0406) were less capable to induce T cell 
responses than FS. This indicated that the peptide presenting efficiency of DQ8 in the presence 
of distinct DRB1*04 alleles were different.  Effects of these DRB1*04 alleles were in the rank of 
0402 ≤ 0401 < 0404 < 0403/0406.  The DRB1*0403/0406+ KT17 always required 5-10 fold 
more peptide to achieve an equivalent T cell response as DRB1*0402+ FS did. It suggested that 
DRB1*0403/0406 alleles had a much stronger competition for these peptides than the 
DRB1*0402 allele. To further confirm this observation, the KT17 was mixed with FS to 
stimulate TH536.1. The group with the mixed presenter (20,000/well FS + 10,000/well KT17) 
caused a reduced level of IL-2 secretion in comparison with the group of pure FS (20,000/well) 
(Figure 33). It indicated that in the KT17/FS mixture, the number of available hGAD65536-
550:DQ8 complex was decreased, though more DQ8 input was provided. 
4.4 DR4 also competed with DQ8 for the peptide delivered by CLIP-substituted 
recombinant invariant chain 
In addition to using synthesized peptides as the source of antigen, we also attempted an 
alternative peptide delivery method for T cell assay. It was accomplished  by transfecting a 
recombinant MHC Class II-associated invariant chain cDNA that carried peptide coding 
sequence to DQ8+ target cells. Previous studies demonstrated that a recombinant Ii (rIi) with its 
original CLIP replaced by an antigenic peptide coding sequence could successfully deliver 
 76 
antigenic peptide to the MHC Class II (160, 161). It allowed target cells to generate antigen 
endogenously so that it provided the possibility to investigate the peptide competition within the 
intracellular compartment.  
 
DQ8#114, a DQ8-transfected COS7 cell clone was used as the target cell. This clone was 
qualified to serve as antigen presenting cell not only because it stably expressed DQ8 
heterodimer on the surface (Figure 34A), but also was able to present exogenous cognate 
peptide hGAD65536-550 to TH536.1 hybridoma (Figure 34B). DQ8#114 was transfected by rIi-
539 – the recombinant invariant chain bearing TH536.1 hybridoma cognate peptide coding 
sequence (Figure 15). TH536.1 was added into the culture 24 hours later. IL-2 secretion 
indicated that rIi-539 could be endogenously processed and presented to the surface to trigger T 
cell response. When DQ8*114 was co-transfected by rIi-539 and DR4, the IL-2 secretion level 
was decreased (Figure 35). The input of TH536.1 hybridomas was titrated down from 105 
cells/well to 104 cells/well. The rIi-539/DR4 co-transfection group consistently elicited lower 
hybridoma responses than the group without DR4 expression. It indicated that the efficiency of 
hGAD65539-547 presentation was reduced in the presence of DR4. 
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Figure 16. The genotype of an HLA transgenic mouse identified by flow cytometry analysis using 
fluorescence-conjugated anti-HLA-DQ and –DR monoclonal antibodies 
Red blood lysis buffer pre-treated mouse peripheral blood sample was analyzed by flow cytometer. (A) The dot plot 
distinguished white blood cells from non-depleted red blood cells or dead cells by relative large size (indicated by 
the value of forward-scatter channel or FSC) and low granule intensity (indicated by the value of side-scatter 
channel or SSC). (B). Among gated white blood cell population, B lymphocytes subset was distinguished from 
others by the expression of surface marker B220 (CD45R), revealed by APC-conjugated anti-B220 mAb staining. 
(C), (D), (E) and (F) FITC-conjugated anti-HLA-DQ mAb and PE-conjugated anti-HLA-DR mAb staining patterns 
of B lymphocytes (gated from B220+ cell populations) from different transgenic mice indicated the HLA genotypes 
were DQ8+DR4+ (C), DQ8+DR4- (D), DQ8-DR4+ (E), and DQ8-DR4- (F), respectively.  
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Figure 17. The generation of antigen-specific CD4 T cell lines from HLA-DQ8 transgenic mice 
 (A) A brief illustration of the protocol used for in vitro T cell line generation. A group (generally, 4 mice) of 6-8 
week old female HLA-DQ8 transgenic mice were immunized by antigenic peptide subcutaneously. Primary culture 
was then established one week later from the spleen and draining lymph node cells. The culture was passaged every 
two weeks after a single one-week culturing. The culture was then characterized for antigen specificity and 
homogeneity by in vitro T cell restimulation assay and flow cytometry analysis or RT-PCR for TCR Vβ usage, 
respectively. Selected T cell lines were also fused with T lymphoma to generate T hybridomas. (B) In restimulation 
culture, activated antigen-specific CD4 T cells displayed enlarged size with episodic clustering under microscope 
(x400). (C) In contrast, non-antigen-specific (without activation) cells display homogeneously small size without 
clustering (x400). 
                                                                                           
B C 
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Figure 18. DQ8-restricted T cell lines specifically responded to cognate peptides 
In vitro proliferation of CD4+ T cell lines DQ8p101 (A), DQ8p121 (B), DQ8p206 (C), and DQ8p536 (D) co-
cultured with irradiated syngenic DQ8+ splenocytes in the presence of medium alone (as blank control) or 10 ug/ml 
of cognate peptide (hGAD65101-115, hGAD65121-140, hGAD65206-220, and hGAD65536-550, respectively). 
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Figure 19. Characterization of clonal T206 cell. 
(A) CD4 T cell line T206 was stained by a panel of FITC-conjugated anti-TCR Vβ mAb for flow cytometry 
analysis. The histogram represents staining results of Vβ6-specific mAb (thick line) and isotype control antibody 
(thin line). (B) cDNA and amino acid sequence of T206 cell TCR β-chain VDJC joint. (C) IFN-γ and IL-4 produced 
by T206 cell as co-cultured with irradiated syngenic DQ8+ splenocytes in the presence of medium (blank control), or 
10 ug/ml cognate peptide hGAD65206-220, or 10 ug/ml unrelated control peptide hGAD65536-550. 
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Figure 20. Characterization of clonal T536.1 cell 
(A) DQ8p536 cells consist of Vβ11- and Vβ11+ subset, revealed by Flow cytometry analysis with PE-
conjugated anti-CD4 mAb and FITC-conjugated anti-Vβ11 mAb double staining. Vβ11- subset was 
separated from Vβ11+ subset by cell sorter and named T536.1. (B) cDNA and amino acid sequence of 
T536.1 cell TCR β-chain VDJC joint. (C). IFN-γ and IL-4 produced by T536.1 cell cultured with 
irradiated syngenic DQ8+ splenocytes in the presence of medium alone (blank control), or 10 ug/ml 
cognate peptide hGAD65536-550 (p536), or 10 ug/ml unrelated control peptide hGAD65206-220 (p206). 
C 
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Figure 21. Characterization of clonal T536.2 cell 
 (A) CD4 T cell line T536.2 (separated apart from T536.1 by cell sorter) was stained by a panel of FITC-conjugated 
anti-TCR Vβ mAb for flow cytometry analysis. The histogram represented staining results of Vβ11-specific mAb 
(thick line) and isotype control antibody (thin line). (B) cDNA and amino acid sequence of T536.2 cell TCR β-chain 
VDJC joint. (C) IFN-γ and IL-4 produced by T536.2 cell co-cultured with irradiated syngenic DQ8+ splenocytes in 
the presence of medium alone (blank control), or 10 ug/ml cognate peptide hGAD65536-550 (p536), or 10 ug/ml 
unrelated control peptide hGAD65206-220 (p206). 
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Figure 22. T206-derived T hybridomas – TH206. 
 (A) Hybridomas surviving HAT selection were screened for CD3 and TCR Vβ6 expression by flow cytometry 
analysis. Dot plot represented one of candidate T hybridomas expressing both CD3 and Vβ6 – the same TCR Vβ 
expressed by parental T206 cell. (B) IL-2 produced by a panel of CD3+Vβ6+ hybridomas co-cultured with irradiated 
DQ8+ splenocytes in the presence of medium alone (no Ag: as blank control) or with 10 ug/ml cognate peptide 
hGAD65206-220. Non-fused fusion partner BWα−β− was also tested under the same assay condition as negative 
control.  
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Figure 23. T536.1-derived T hybridomas – TH536.1 
IL-2 produced by a panel of hybridomas co-cultured with medium alone (as blank control), or 10 ug/ml cognate 
peptide hGAD65536-550, or 10 ug/ml unrelated control peptide hGAD65121-140 in the presence of irradiated DQ8+ 
splenocytes. Non-fused fusion partner BWα-β- was also tested under the same assay condition as negative control. 
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Figure 24. T536.2-derived T hybridomas – TH536.2 
(A) Hybridomas surviving HAT selection were screened for CD3 and TCR Vβ11 expression by flow cytometry 
analysis. Dot plot represents one of candidate T hybridomas expressing both CD3 and Vβ11 – the same TCR Vβ 
expressed by parental T536.2 cell. (B) IL-2 produced by a panel of CD3+Vβ11+ hybridomas co-cultured with 
irradiated DQ8+ splenocytes in the presence of medium alone (no peptide: as blank control) or 10 ug/ml cognate 
peptide hGAD65536-550 (p536). Non-fused fusion partner BWα-β- was also tested under the same assay condition as 
negative control. 
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Figure 25. In vitro T cell response of DR4p206 cells 
IFN-γ produced by DR4p206 cell co-cultured with irradiated DQ8+ splenocytes, DR4+ splenocytes or DQ8+DR4+ 
splenocytes in the presence of medium alone (as blank control), or 10ug/ml of cognate peptide hGAD65206-220. 
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Figure 26. Influence of HLA-DR4 (0401) co-expression to antigen specific DQ8-restricted CD4 T cell 
responses. 
(A) RBC-depleted splenocytes from DQ8 (thick lines) and DQ8/DR4 transgenic mice (thin lines) were stained with 
FITC-conjugated anti-HLA-DQ mAb (left panel), and PE-conjugated anti-HLA-DR mAb (right panel). Dotted line 
represents isotype control. Cytokine produced by T206 (B), T536.1 (C), and T536.2 (D) co-cultured with DQ8+ 
splenocytes or DQ8+DR4+ splenocytes in the presence of indicated amount of cognate peptides.   
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Figure 27. T536.2 cells expand poorly in comparison to T536.1 cells upon in vitro antigen restimulation. 
(A) Proliferation of T536.1 and T536.2 cell co-cultured with irradiated syngenic DQ8+ splenocytes in the presence 
of indicated amount of cognate peptide hGAD65536-550. (B) Proliferation of T536.1 cell co-cultured with irradiated 
DQ8+, or DQ8+DR4+ splenocytes in the presence of indicated amount of cognate peptide hGAD65536-550. 
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Figure 28. Blocking of DR4 binding site partially recovered DQ8-restricted T hybridoma responses 
IL-2 produced by T hybridoma TH206 (A), TH536.1 (B) and TH536.2 (C) co-cultured with WT51 (human B cell 
line, DQ8+DR4+) in the presence of cognate peptides (10 ug/ml of hGAD65209-217 for TH206, 2 ug/ml of hGAD65536-
550 for TH536.1 and TH536.2) and indicated amount of blocking peptide hGAD65554-566, which bound only DR4 but 
not DQ8. 
B 
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Figure 29. Alignment of selected DRB1*04 alleles 
Peptide binding region amino acid sequences of DRB1*0402, 0403, 0404, 0405 and 0406 were aligned to 
DRB1*0401 (as reference). Short dashes represent the usage of identical amino acid residues. DRB1*0403 and 
DRB1*0406 share the identical sequence regarding peptide binding groove related fragment. The cartoon was 
adapted from 2SEB, a crystal structure file collected in Protein Database Bank (PDB), this ribbon and stick model 
summaries the association a peptide (ball-stick) from human Collagen II (1168-1179) with peptide binding groove 
of HLA-DR4 composed of DRA1*0101 (the ribbon at low position in dark color) and DRB1*0401 (the ribbon at up 
position in light color). Portions on β-chain highlighted as space-filled style represent amino acid residues differing 
DRB1*0401 from other DRB1*04 alleles according to the alignment. (adapted from reference 101 with slight 
modification) 
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Figure 30. TH206 hybridoma responded to truncated 9-mers and a cognate 15-mer (hGAD65206-220). 
IL-2 produced by TH206 hybridoma co-cultured with Mitomycin C treated WT51 (a human B cell line expressing 
HLA-DQ8) in the presence a panel of partially overlapped peptide 9-mers, in comparison with hGAD65206-220 15-
mer.  
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Figure 31. CD4+ T hybridoma responses to human B-LCLs expressing different DQ8-DRB1*04 haplotypes 
IL-2 produced by hybridoma TH206 (A), TH536.1 (B), and TH536.2 (C) co-cultured with Mitomycin C treated 
human B-LCL WT51 (0401), FS (0402), KT17 (0403/0406), and BM92 (0404) in the presence of indicated amount 
of cognate peptides.  
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Figure 32. Relative abundance of HLA-DQ and HLA-DR expressed by B-LCLs. 
Relative HLA-DQ (black filled bars) and HLA-DR (opened bars) expression level of human B cell lines. Mean 
fluorescence intensity of anti-HLA-DQ and anti-HLA-DR mAbs staining was normalized, with WT51 DQ and DR 
staining intensity as reference. 
 
 
 
 
 
 
 
 
 
 
Figure 33. TH536.1 responses elicited by FS and FS/KT17 mixture 
IL-2 produced by TH536 (20,000 cells/well) responding to DRB1*0402+ FS (20,000 cells/well) was compared with 
the response to a “mixture” presenter -– DRB1*0402+ FS (20,000 cells/well) plus extra DRB1*0403/0406+ KT17 
(10,000 cells/well).  
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Figure 34. Expression and function of HLA-DQ8 in transfected COS7 cell line 
(A) Histogram represents FITC-conjugated anti-HLA-DQ mAb staining results of HLA-DQ8-transfected COS7 
clone -- DQ8#114 (thick line), and non-transfected COS7 (thin line). Dot line represents antibody isotype control. 
(B) IL-2 produced by TH536.1 hybridoma co-cultured with either DQ8#114 (DQ8+) or COS7 cells in the presence 
of indicated amount of hGAD65536-550, respectively.  
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Figure 35. TH536.1 hybridoma responses elicited by endogenously synthesized peptide 
IL-2 produced by indicated number of TH536.1 hybridoma in the presence of rIi-p539 transfected DQ8#114 ((mock 
DNA/rIi-539)DQ8) or rIi-539/DR4 co-transfected DQ8#114 ((DR4/rIi-539)DQ8). rIi-539 transfected DQ8- 
COS7 ((DR4/rIi-539)COS7) was applied as negative control.  
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5.0  DISCUSSION 
This study addressed an important biological question, namely how certain HLA molecules 
modulate the disease risk conferred by other HLA molecules. HLA molecules under the 
investigation were HLA-DQ8 and HLA-DR4, the two most prevalent HLA Class II alleles found 
in Caucasian Type 1 Diabetes (T1D) patients.  
 
The principle behind this study is that HLA molecules expressed from different alleles 
and/or loci compete with each other to bind peptides to form complexes driving T cell-mediated 
immune responses. Although Nepom proposed this model a decade ago (11), no experimental 
evidence has been shown since then to demonstrate the competition between DQ8 and DR4 
molecules. One big obstacle was that the knowledge about DQ8-diabetogenic peptides was far 
from sufficient. Although autoantibodies against β-cell proteins such as insulin and GAD65 have 
been broadly used for many years to diagnose or predict the development of T1D, autoreactive T 
cell responses against β-cell antigens have not been clarified thoroughly, partially due to 
difficulties of obtaining replicable in vitro T cell assay results, partially due to the complexity of 
human HLA system (people differing from each other for their HLA haplotypes). In addition, 
distinct strategies (such as insect cell expression systems or bacterial expression systems) of 
recombinant protein (of candidate β-cell autoantigen pareparations) for in vitro T cell assays 
generates unexpectedly variability between different labs (162). Another obstacle was the co-
expression of closely linked DQ and DR in human antigen presenting cells so that it was nearly 
impossible to dissect the role of DQ from DR. At the end, it was still not an easy task to have a 
reliable readout system that was sensitive enough to detect the peptide competition. 
 
We thus decided to develop an experimental system to circumvent these barriers to test 
this hypothesis. The approach taken was to generate T cells as reagents. This was accomplished 
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by immunizing HLA-DQ8 transgenic mice in vivo with GAD65-derived peptides. As in this 
transgenic strain, human HLA-DQ8 was the only functional MHC Class II molecule, all CD4 T 
cell responses were restricted to DQ8. It hence allowed us to dissect the effect of DR4 from the 
effect of DQ8. GAD65-derived peptides used in this study were identified as DQ8-restricted T 
epitopes from a previous study, in which a similar HLA-DQ8 transgenic mouse system was used 
(154). Although there was no direct evidence to demonstrate that these peptides were 
diabetogenic, they were found to be the strongest binding peptides (to DQ8) derived from 
GAD65 – one of the most important autoantigens in human T1D. Having obtained a panel of 
CD4 T cell lines, we further confirmed that these T cell lines were not cross-reactive with DR4 
molecules. Therefore, these T cell reagents were qualified as readout systems to evaluate cognate 
peptide occupancy of HLA-DQ8 on various antigen presenting cell surfaces including 
DQ8+DR4- and DQ8+DR4+ APCs. When HLA-DR4 was co-expressed with DQ8, there was a 
reduction in T cell response, which indicated a reduction in peptide/DQ8 occupancy.  
 
Unlike traditional approaches studying the dissociation rate of purified MHC molecules 
and labeled peptide, we didn’t directly examine the affinity between the peptide and MHC 
molecules. However, we addressed the event of antigen presentation that occurred on the cell 
surface, a scenario being more similar to what happens in the immune system than in a “cell-
free” system (binding between purified MHC and labeled peptide). In the “cell-free” system, 
purified protein is dissolved in the solution that not only contains special detergents allowing the 
protein to fold into a proper conformation, but also has a pH and ion strength environment 
preventing the protein from aggregation. However, these in vitro conditions are still very 
different from the condition on the cell surface and intracellular vesicles such as late endosome 
where peptides interacted with HLA/MHC Class II molecules. In the solution, either DQ8 or 
DR4 might fold into a conformation slightly different from their original conformation on the 
cell surface. Then is it unambiguous enough to compare the affinity of a peptide to DQ8 with the 
affinity of the same peptide to DR4? Actually, the relative affinity of a peptide binding to a MHC 
Class II molecule is characterized by the IC50 value, which represents the concentration of a 
tested peptide required to replace 50 % of labeled reference peptide occupancy. The IC50 value is 
thus heavily dependent on the affinity of reference peptide and tested MHC Class II. Apparently, 
reference peptides for DQ8 and DR4 are very different. It was thus not practical to normalize the 
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binding between DQ8 and a peptide to the binding between DR4 and the same peptide. 
Therefore, the cell-free peptide/MHC binding system does not serve our purpose very well.   
 
Since the peptide competition theory is based on the premise that peptides are binding to 
HLA-DR4, it is essential to show that DR4 could bind the candidate peptides. Wicker et al 
previously reported that some GAD65 derived peptides, including GAD65201-220 and GAD65531-
550, were able to bind both DQ8 and DR4 (DRB1*0401) using an MHC Class II binding assay 
(150). Interestingly, these two 20-mers overlap with the peptides we used in this study 
(GAD65206-220 and GAD65536-550). The data from their “cell-free” protein binding assay provides 
chemical evidence that DR4 is able to bind the peptides (hGAD65206-220 and hGAD65536-550) that 
we used to generate DQ8-restricted CD4 T cell lines. In this study, this issue was addressed in an 
alternative approach. Instead of performing peptide binding assay as previously described (150), 
we showed the restimulation assay results of two distinct CD4 T cell lines, DQ8p206 and 
DR4p206 (Figure 18C and Figure 25). DQ8p206 only responded to the cognate peptide 
hGAD65206-220 when it was presented by DQ8, whereas DQ4p206 only responded to hGAD65206-
220 when it was presented by DR4. The evidence from DR4p206 unambiguously demonstrated 
that DR4 was able to bind the same peptide, which was bound DQ8. Therefore, DR4 had 
intrinsic potential to compete for hGAD65206-220 with DQ8.  
 
We also used recombinant hGAD65 whole protein as the antigen for in vitro T cell 
assays. All DQ8-restricted CD4 T cell lines were tested and able to respond to hGAD65 in a 
recall assay at early stage of the study. Lately, however, these T cell lines surprisingly lost their 
responses to the same batch of hGAD65 whole protein. It is possible that the recombinant protein 
became modified and lost its predominant epitopes due to a suboptimal storing condition and 
was thus unable to be processed and presented onto the cell surface properly. The recombinant 
hGAD65 used in this study was expressed in sf9 cell (an insect cell line) using baculovirus 
expressing system, and was purified by Ni-NTA affinity column that bound the 6xHis tag on the 
C-terminal of recombinant protein. After being dialyzed into imidozale-free sodium phosphate 
buffer, the protein was concentrated and stored in the buffer at 4 ºC. After a few months, we 
observed that the protein solution started to be more and more “cloudy” and finally white 
precipitant was formed. By using SDS-PAGE, we found out that the white precipitant was 
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actually the aggregation of pure hGAD65 protein. Therefore, the spontaneous aggregation of the 
protein under 4 ºC might account for the loss of antigenesis. In addition, the reference indicates 
that oxidation is another modification during a long-term storage (163-165). It occurs most 
readily at methionine and cysteine residues as well as those that possess aromatic side-chains 
such as phenylalanine, histidine, tyrosine and tryptophan. It has been widely acknowledged that 
side-chains of amino acids are involved in the interaction between the peptide and HLA/MHC 
molecules. The modification of the side-chain might cause improper interaction to HLA/MHC 
molecules. It is noteworthy that the hGAD65206-220 possesses a phenylalanine within the core 
region that is required for the binding, and hGAD65536-550 possesses two tyrosine residues and a 
methionine within its core region. Thus, it was very likely that the oxidation modified side-
chains of important amino acids involved in interacting with DQ8, including those that located 
within hGAD65206-220 region and hGAD65536-550 region and caused the loss of antigenesis of the 
protein. 
 
Although in total we obtained five DQ8-restricted CD4 T cell lines, we only chose three 
of them –T206, T536.1 and T536.2 as reagents for further study. The major consideration was 
that these three T cell lines had low background responses in the absence of cognate peptide, and 
more important, the composition of these three cell lines was homogeneous (revealed by 
analyzing the usage of TCR β-chain).  In contrast, another two lines DQ8p101 and DQ8p121 
didn’t serve these two criteria so well. Many different strategies could still be tried to improve 
the purity of cell lines, but we decided not to do it for time considerations. By having three 
homogeneous cell lines, we had sufficient confidence to accomplish the experiment and draw the 
conclusion from it, especially we had direct evidence that one of peptides hGAD65206-220 was 
able to bind both DQ8 and DR4. 
 
The consequence of peptide competition, revealed in our study as reduced IFN-γ 
production and reduced Th1 cell clonal expansion (Figure 26B, 26C and 27B), may explain the 
moderate insulitis, and reduced diabetes incidence observed in DQ8+DR4+ transgenic mice, in 
comparison with DQ8+DR4- transgenic mice (10). As IFN-γ is responsible for 
immunopathogenesis at different stages of β-cell destruction (56), the variation of IFN-γ 
production influences: 1) antigen processing/presenting by controlling MHC Class I/II and co-
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stimulatory molecule expression, 2) recruitment of other islet-reactive leukocytes by regulating 
the expression of adhesive molecules, chemokines and their receptors on endothelia, 3) β-cell 
apoptosis. The impact of IFN-γ is further synergized by clonal expansion. Thus, the diminished 
IFN-γ production, together with reduced Th1 cell expansion is relevant to interpret the regulatory 
role of DR4 to autoimmune diabetes susceptibility conferred by DQ8.  
 
Two issues were raised when we designed the experiment to compare T cell responses 
elicited by DQ8+ splenocytes vs. DQ8+DR4+ splenocytes. One issue concerned the expression 
level of DQ8 on the surface of antigen presenting cells from different sources. The copy number 
of the DQ8 transgene in experimental animals might have dose effect and determine DQ8 
expression level. Therefore, it would be meaningless if we intended to test the hypothesis that the 
peptide occupancy of DQ8 was reduced in the presence of DR4 by using DQ8+DR4+ APCs with 
intrinsically lower DQ8 expression on the surface than DQ8+ APCs. This issue was realized and 
circumvented by quantitatively examining a group of pups for both DQ8 and DR4 expression. 
Flow cytometry analysis revealed not only the frequency but also the (anti-HLA mAb staining) 
intensity of DQ8+ cells. Accordingly, we could easily choose mice with similar DQ8 expression 
patterns as sources of APCs. A second issue concerned the presence of non-antigen presenting 
cells within splenocyte population. It was suspected that the number of CD4+CD25+ T cells – 
Treg cells was different in splenocytes from different mice. We repeated the experiment using T 
cell-depleted splenocytes as APCs so that all possible Treg cells, non-specific CD4, CD8 T cells 
(dead or alive) interference were removed from the system. Results were similar to what we 
presented in this thesis (Figure 26B, 26C and 26D). Actually, the effect of Treg cell was beyond 
the scope of the dissertation. The Treg cells were still mysterious with respects to how they were 
selected in the thymus, what their antigen specificity was about, how they obtained activation 
and how they suppressed other T cells. In addition, the experiment in this study used irradiated 
splenocytes as antigen presenting cells. Irradiation should disable Treg cell activity (if there was 
any). Therefore, there was no strong reason that Treg cells would confound our results.  
 
Further evidence for peptide competition would be that the competition should be 
inhibited by DR4 blockade.  An anti-HLA-DR monoclonal antibody was originally considered to 
serve this purpose. However, it was not clear whether antibody binding would affect peptides to 
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access the DR4 peptide binding site. In other words, anti-DR antibody would not necessary 
inhibit DR4 peptide binding. In addition, antibody only bound to DR4 molecules on the surface 
but not DR4 molecules located within intracellular vesicles Therefore, antibody blockade was 
not able to serve this purpose perfectly. Another choice was a peptide that had been 
demonstrated to bind only DR4 but not DQ8. As this blocking peptide shared similar molecular 
weight (9 to 15 amino acid residues) and conformation (linear conformation, without 
complicated secondary structure) with cognate peptide, they could access DR4 peptide binding 
sites as readily as cognate peptide. The outcome of peptide blockade was very clear (Figure 
28A, 28B, and 28C). By using as low as 2 ug/ml of blocking peptide, we observed the recovery 
of all three DQ8-restricted CD4 T cell responses. It implicated that this blocking peptide bound 
DR4 with higher priority than DQ8 cognate peptide. It also strongly supported our conclusion 
that the co-expression of DR4 competed for peptides with DQ8 and consequently diminished 
DQ8-restrcited T cell responses. Actually, the decision of choosing this particular peptide – 
hGAD65554-566 as a blockade was based on binding affinity of DR4 with the peptide from a 
previous study (150). According to the same information from that study, we also chose another 
peptide – hGAD65274-286 only binding to DR4 but not DQ8 to serve the blockade purpose. The 
result however was less supportive than blocking peptide hGAD65554-566. We could only observe 
the recovery of DQ8-restricted T cell responses when high dose (>10 ug/ml) of hGAD65274-286 
blockade was applied.  We then realized this second blocking peptide bound DR4 with lower 
affinity than the first blocking peptide. Increasing amount of blocking peptide was thus required 
to occupy DR4 binding groove effectively. 
 
A surprising fact from previous studies trying to clone CD4 T cells from peripheral blood 
of T1D patients was that all T cells were restricted to DR4 instead of DQ8 (6). There were two 
issues related to the techniques for in vitro human T cell culturing that possibly generated this 
outcome. 1) Within the peripheral blood lymphocytes (PBL)—the primary source for in vitro T 
cell cloning, the frequency of DR4-restricted T cells was much higher than the frequency of 
DQ8-restricted T cells. 2) The protocol of cloning human T cells required autologus APCs that 
are normally obtained from the PBL of the same human subject where T cells came from. The 
APCs (mainly B cells) thus express DQ, DR and other HLA molecules. Therefore, both DR4-
restricted T cells and DQ8-restricted T cells would have a chance to be activated and expand 
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upon antigen restimulation. At this point, the peptide competition demonstrated by our results 
might serve as another explanation of unsuccessful cloning of DQ8-restrcited T cells from 
human PBL. Under the competition of DR4, DQ8-restricted T cells would be in a disadvantage 
regarding the antigen sources required for their expansion. On the other hand, DR4-restricted T 
cells, with high starting frequencies, have many growth advantages over DQ8-restricted T cells. 
Accordingly, the peptide competition should be paid more attention in the efforts aimed to clone 
human DQ8-restricted T cells from human peripheral blood lymphocyte. For an instance, 
perhaps the addition of DR4 blockade peptide to block DR4 peptide binding site might increase 
the odds to obtain a DQ8-restricted T cell line. 
 
Since we demonstrated that DR4 (0401) competed with DQ8 for the peptide, we further 
pursued the competition potential of other individual DR4 alleles. We believed that it extended 
our understanding to some subtle aspects of HLA genetics in T1D, saying the different T1D 
association of distinct DR4 subtypes (0401, 0402, 0403, 0404, 0405, and 0406) that also closely 
linked with DQ8 susceptible genes. DQ8-DR4 haplotypes with DRB1*0405, 0402, 0401, 0404, 
0403 and 0406 were all associated with T1D but with decreased relative risk, in the order of 
0405>0402>0401>0404>0403, 0406. The 0405, 0402 and 0401 haplotypes were still disease 
susceptible, while the 0404 haplotype was neutral and the 0403/0406 haplotype were disease 
resistant. A straightforward interpretation was that these DRB1*04 alleles had a variable affinity 
for same diabetogenic peptides that bound DQ8 in T1D. However, relative affinities for peptide 
binding were in the order of 0405<0402<0401<0404<0403, 0406. In this way, DRB1*0403 or 
0406 manifested the strongest competition capacity with DQ8 for diabetogenic peptides and was 
able to maximally diminish DQ8-restricted autoreactive T cell responses. Therefore, the DQ8-
DRB1*0403/0406 haplotype were disease resistant, in comparison with other DQ8-DRB1*04 
haplotypes. On the other hand, DRB1*0401 only manifested an intermediate level of competition 
potential and was still able to diminish DQ8-restricted autoreactive T cell responses, but the 
effect was weaker than that of DRB1*0403/0406 alleles. As for the DRB1*0405 and 0402, these 
two alleles probably had the weakest competition capacity for diabetogenic peptides and were 
not able to affect DQ8-restricted autoreactive T cell responses at all. Therefore, DQ8-
DRB1*0405 and DQ8-DRB1*0402 haplotypes were associated with T1D with the highest risk. 
Our results didn’t show relative affinities of this panel of DR4 subtypes to peptide hGAD65209-217 
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or hGAD65536-550 because we didn’t have the intention to express/purify all these HLA-DR4 
molecules in a great amount and make them re-fold into an appropriate conformation so that the 
direct peptide binding assay could be applied. However, we addressed this question in a simple 
alternative way – showing effects of this panel of DRB1*04 alleles to DQ8-restricted T cell 
responses. Results were quite consistent with what was assumed under the hypothesis of the 
peptide competition model (Figure 31A, 31B, and 31C). All three T hybridoma responses 
elicited by a panel of B cells carrying different DQ8-DRB1*04 haplotypes were in the order of 
0402 >0401>0404>0403/0406. For the KT17—the B cell expressing DRB1*0403/0406, it 
always needed as much as 5 to 10-fold more peptide to induce a T cell response equivalent to 
that induced by another B cell line – FS that expressed DRB1*0402. It indirectly suggested that 
0403/0406 was much more capable of competing for peptides than 0402 allele. It has been 
widely discussed by many previous reports about the association between polymorphisms within 
the peptide binding groove and relative risk to T1D. Variable degrees of protection conferred by 
distinct DRB1*04 alleles were primarily determined by amino acid sequences within peptide 
binding grooves. According to the sequence alignment shown in (Figure 29), it was clear that 
amino acid differences among distinct DRB1*04 alleles rendered each individual allele a distinct 
peptide binding capability that could be correlated with their different peptide competition 
potentials. It gave the explanation at the level of molecular structures to support what we 
observed in our T hybridoma assay.  
 
Unable to obtain a B cell line homozygously expressing DQ8-DRB1*0405 haplotype 
made our study a little bit less ideal. As all B cell lines used in this study and many other antigen 
presenting studies were obtained from EBV-transformed human PBL B cell, the availability of a 
B cell line expressing a desirable haplotype was depending on the availability of such a 
haplotype in general population. DRB1*0405 was actually a rare allele and was only relatively 
enriched in Sardinia, Italy. We contacted investigators in Sardinia who most possibly had 
DRB1*0405+ patient blood samples. Unfortunately, a DQ8-DRB*0405 homozygous sample was 
still not available. 
 
It is noteworthy that our results were obtained from in vitro T cell assays using 
activated/effector T cells to evaluate peptide occupancy. The decreased T cell responses caused 
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by peptide competition implied more profound biological significance under in vivo situations, 
where the autoantigen resource was limited, the frequency of autoreactive T cell was low, and 
most T cells expressed naïve phenotypes. Mature/effector T cells and naïve/immature T cells 
have been known to be different regarding the requirements for activation. For the naïve T cells, 
the quantity of TCR:peptide:DQ8 engagement had to reach a threshold (~8,000 TCR/cell) to 
obtain activation, otherwise, these autoreactive T cells are “silenced” or anergic (124, 166). 
Although co-stimulation lowers the requirement to one fifth as great, the number of available 
self-peptide:DQ8 complex on the APCs is still a crucial parameter to direct naïve autoreactive T 
cells to differentiate into harmful effector Th1 cells, or become nonresponsive. It was more 
critical for the cells that naturally have lower TCR numbers. They might require an unattainably 
high concentration of antigen to engage enough TCRs for a “successful” activation. Indeed, T 
cells that escaped thymic selection with potentially autoreactive TCRs often intrinsically had a 
lower TCR density on their surface (167).   
 
There was no doubt that the expression of DR4 MHC Class II directed positive selection 
of TCRs with novel specificities, and some of those might potentially recognized islet antigen 
derived peptides. Whether those DR4-restricted CD4 T cells regulated DQ8-restricted 
autoreactive T cells via secreting “protective” Th2 cytokines such as IL4/IL-10, or whether some 
of those DR4-restricted T cells developed into Treg cells, was not addressed in this experimental 
model.  
 
Our observations provided in vitro evidence for peptide competition as an explanation of 
the modulatory role of DR4 in the T cell response to diabetes related autoantigens. Our T cell 
response data was consistent to the hierarchical association of different DQ8-DRB1*04 
haplotypes with T1D susceptibility by bridging protein structure studies with genetic analysis. In 
addition, the TCR information we obtained from re-cloned hybridomas might help us develop an 
in vivo model to investigate the regulatory role of the DR4 to DQ8 restricted T cell response. 
Considering the DQ8-DR4 was the most prevalent haplotype in the Caucasian T1D population, 
the efforts to increase the regulatory effect, particularly in the prediabetic or earlier stages might 
provide novel therapeutic strategies to interfere with autoimmune progression. 
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6.0  CONCLUSION 
 
1. HLA-DQ8 and HLA-DR4 are able to bind the same peptides, including peptides 
derived from putative autoantigens of T1D such as GAD65 
 
2. The presence of HLA-DR4 reduces DQ8-peptide occupancy. 
 
3. The outcome of the peptide competition diminishes Th1 cell responses regarding 
both cytokine production and proliferation, whereas it has less effect to Th2 
responses. 
 
4. The polymorphisms within peptide binding sites of different DR4 alleles are 
associated to variable peptide competition capacities.  
 
5. DR4 also competes with DQ8 for peptides within the intracellular compartment. 
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